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 Many immune cell receptors are modular in design; the ligand binding function 
and signaling capacity are separated into two different elements. One common signaling 
adaptor molecule expressed in both Natural Killer and T cells is CD247. 
 The opportunity to study immune cells from a CD247 deficient patient let us 
analyze the effects of the lack of this adaptor module on human lymphocyte biology. In 
the absence of CD247, T cell receptor assembly was compromised and its expression at 
the cell surface markedly diminished, abrogating antigen-specific immune responses by 
the patient and increasing susceptibility to infections. With regard to NK cells, surface 
expression of CD247-coupled receptors and their function after specific ligation was 
compromised. Moreover, as well as these direct effects, the absence of functional T cells 
also impaired NK cell development and proper maturation indirectly.  
 Consistent with prior studies on CD247-deficient patients, it was possible to detect 
revertant T and NK cells in this particular patient. Subsequent genetic analyses of the 
patients T cells, after brief in vitro expansion, revealed two classes of revertant cells: a true 
back mutation and a compensatory mutation, both compatible with restored CD247 
protein expression and T cell receptor assembly. This reversion phenomenon has been 
reported for only a set of genes affected in PIDs. Further informatics analysis of the genetic 
variation in other PID genes where reversion has been reported showed a higher rate of 
missense variants in the coding sequence of these genes compared to PID affected genes 
with no reversion cases or control genes, leading to the hypothesis that the occurrence of 
somatic mutations that reconstitute genetic defects in PID is related to an increased 
propensity of those genes to mutate. 
 To date, the interactions that mediate CD247 assembly with counterpart receptors 
depend on contacts between single transmembrane residues of opposing charge. 
However, CD16A does not contain a positively charged residue in its transmembrane 
domain. Detailed biochemical study of CD16A receptor complex formation revealed a 
novel mode of assembly based on multiple polar and aromatic interactions that could be 
extended to other Fc receptors, CD64 and FcR1. 
Altogether, our results illustrate how the human immune system adapts, escapes 
by reversion of genetic defects and the biochemical plasticity of CD247 signaling adaptor 
module demonstrated by the ability to couple many receptors by different mechanisms.  
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 La gran mayoría de los receptores inmunes tienen un diseño modular; la 
capacidad de unirse a sus ligandos y de señalizar recae en subunidades diferentes. 
CD247 es un módulo de señalización común a células T y Natural Killer. 
 La ocasión de estudiar el sistema inmunitario de un paciente deficiente en 
CD247 ha permitido analizar las consecuencias de la ausencia de esta molécula 
adaptadora en la biología de los linfocitos humanos. En ausencia de CD247, el 
ensamblaje del TCR se ve comprometido y su expresión en superficie es prácticamente 
nula, impidiendo las respuestas antígeno específicas y aumentando la susceptibilidad a 
infecciones del paciente. En cuanto a las células NK, la expresión en superficie y la 
respuesta a través de receptores que se asocian a CD247 está disminuida. Además de 
estos efectos directos, la ausencia de células T funcionales afecta de manera indirecta 
al correcto desarrollo y maduración de las células NK. 
 Al igual que en los pacientes deficientes en CD247 previamente descritos, 
detectamos células T y NK revertientes. El análisis genético de células T del paciente, 
tras una breve expansión in vitro, reveló la existencia de dos clases de revertientes: 
una retromutación y una mutación compensatoria, permitiendo ambas recuperar la 
expresión de la proteína CD247 y el ensamblaje del TCR. Se han encontrado eventos de 
reversión en solo algunos de los genes afectados en inmunodeficiencias primarias 
(IDPs). El análisis de la variación genética en el resto de genes revertientes mostró una 
mayor tasa de mutaciones sin sentido en la región codificante, comparado a otros 
genes afectados en IDPs sin eventos de reversión descritos o en genes control. Este 
hallazgo hizo plantear como hipótesis que la probabilidad de revertir un defecto 
genético está relacionada con la propensión intrínseca de dicho gen a mutar. 
 Hasta la fecha, la asociación de CD247 a sus receptores se basa en una única 
interacción mediada por residuos de carga opuesta. Sin embargo, CD16A no contiene 
un residuo cargado positivamente en su región transmembrana. El estudio bioquímico 
de la interacción de CD16A con sus módulos de señalización reveló un nuevo modelo 
de ensamblaje basado en múltiples interacciones polares y aromáticas. Además, se 
demostró que este modelo podría aplicarse a otros receptores de Fc, CD64 y FcR1. 
 En resumen, estos resultados ilustran como el sistema inmunitario se adapta, 
revierte los defectos genéticos y demuestra la plasticidad del módulo de señalización 
CD247 para unirse a distintos receptores mediante diferentes mecanismos. 
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Ab     Antibody 
ADA     Adenosine deaminase 
ADCC     Antibody dependent cell cytotoxicity 
BCR     B cell receptor 
CARD11    Caspase recruitment domain 11 
CD     Cluster of differentiation 
cDNA     Complementary deoxyribonucleic acid 
CID     Combined Immunodeficiency 
CNV     Copy number variation 
CO2     Carbon dioxide    
CXCR4     C-X-C chemokine receptor type 4 
DMEM     Dulbecco´s Modified Eagle medium 
DNA     Deoxyribonucleic acid 
DOCK8     Dedicator of cytokinesis 8 
EGFP     Enhanced green fluorescence protein 
ER     Endoplasmic reticulum 
F     Forward 
FAS     First apoptosis signal 
Fc     Fragment crystallizable 
FcR     Fc receptors 
FCS     Foetal calf serum 
FcαR     Fc-alpha receptors 
FcγR     Fc-gamma receptors 
FcεR     Fc-epsilon receptors 
FynT     Fyn tyrosine 
GeoMFI    Geometric mean fluorescence intensity 
GlcNAc    β-N-acetylglucosamine 
GPI     Glycosylphosphatidylinositol 
Grb2     Growth factor receptor-bound protein 2 
HCMV     Human cytomegalovirus 
HIV     Human immunodeficiency virus 
HLA     Human leukocyte antigen 
  
 
19 
 
cc/ 
Dar
HSC     Hematopoietic stem cell 
ICOS     Inducible T cell co-stimulator 
IDP     Inmunodeficiencia primaria 
IFN     Interferon 
Ig     Immunoglobulin 
IgAD     Immunoglobulin A deficiency 
IKBKG     Inhibitor of kappa B kinase gamma 
IL     Interleukin 
IL-R     Interleukin - receptor 
IP3     Inositol triphosphate 
IP4     Inositol tetrakisphosphate 
IRAK4     Interleukin-1 receptor-associated kinase 4 
IRF8     Interferon regulatory factor 8 
ISG15     Interferon (IFN)-stimulated gene 15 
ITAM     Immunoreceptor tyrosine based activating motif 
ITIM     Immunoreceptor tyrosine-based inhibition motif 
IUIS     International Union of Immunological Societies 
IVT     In vitro transcription 
JAK3     Janus Kinase 3 
KIR     Killer-cell immunoglobulin-like receptors 
LIG1     Ligase 1 
mAb     Monoclonal antibody 
MALT     Mucosa-associated lymphoid tissue 
MCMV     Mouse cytomegalovirus 
Med-Golgi    Medial-Golgi 
MFI     Mean fluorescence intensity 
MHC     Major histocompatibility complex 
min     Minutes 
MIP1a/B    Macrophage Inflammatory Proteins 
MIRR      Multisubunit immune-recognition receptor 
mL     Milliliter 
mM     Millimolar 
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MMR     Mismatch repair 
mRNA     Messenger Ribonucleic acid 
NCR     Natural Cytotoxicity Receptor 
NEMO     Nuclear factor-κB essential modulator 
NK     Natural Killer 
nm     Nanometre 
NMR     Nuclear magnetic resonance 
PBA     PBS-azide 
PBMC     Peripheral blood mononuclear cell 
PBS     Phosphate-buffered saline 
PCR     Polymerase chain reaction 
PE      Phycoerythrin 
PI3K     Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PID     Primary Immunodeficiency 
PM     Plasma membrane 
qPCR     Quantitative polymerase chain reaction 
R     Reverse 
RAG 1/2    Recombination-activating gene enzymes 1/2 
RNA     Ribonucleic acid 
RT     Reverse transcription 
SAP     SLAM associated protein 
SD     Standard deviation 
SH2     Src homology 2 
SH2D1A    SH2 domain–containing protein 1A 
SHIP     SH2-containing polyinositol phosphatase 
SHP-1/2    SH2-containing protein tyrosine phosphatase 1/2 
SLE     Systemic lupus erythematosus 
SMFS     Single-molecule force spectroscopy 
SNP     Single nucleotide polymorphisms 
STAT1     Signal transducer and activator of transcription 1 
TCR     T cell receptor 
TGF     Transforming growth factor 
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TGFBR1    TGF-beta receptor type-1 
TGN     Trans-Golgi network 
TM     Transmembrane 
TMD     Transmembrane domain 
TNF     Tumor necrosis factor 
TRAPS     TNF - Receptor-Associated Periodic Syndrome 
TWEAK    TNF - related weak inducer of apoptosis 
U     Unit 
v/v     Volume/volume 
w/v     Weight/Volume 
WAS     Wiskott–Aldrich syndrome protein 
wt     Wild type 
ZAP70     Zeta-chain-associated protein kinase 70 
ºC     Degree Celsius
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1. PRIMARY IMMUNODEFICIENCIES: 
1.1. Definition and classification: 
 Primary immunodeficiency diseases (PID) are a group of more than 300 rare, 
chronic disorders in which part of the body’s immune system is missing or functions 
improperly [1]. These diseases are not contagious, rather they are caused by 
hereditary or spontaneous genetic defects, and, although most disorders present at 
birth or in early childhood, the disorders can manifest themselves at any age. 
 In contrast, secondary immunodeficiencies occur during certain viral 
infections, after immunosuppression to prevent graft rejection after transplantation, 
during treatment of systemic autoimmune disease, and in association with cancer and 
chemotherapy [1]. 
 Some PIDs affect a single part of the immune system, while others may affect 
one or more components of the system. Although, the specific symptoms may differ 
between diseases, they all share an increased susceptibility and severity to infection. 
Moreover, common features often include immune dysregulation with autoimmune 
disease, lymphoproliferation, aberrant inflammatory responses and malignancy [1]. 
 With the exception of IgA deficiency (IgAD), which occurs with a high incidence 
of 1:500 newborns [2], all other forms of PID are rare and have an overall prevalence 
of approximately 1:10,000 live births; however, a much higher rate is observed among 
populations with high rates of consanguinity or among genetically isolated 
populations. PIDs are classified according to the component of the immune system 
that is primarily involved.  The Expert Committee for Primary Immunodeficiency of the 
International Union of Immunological Societies (IUIS) classified PIDs into 8 general 
categories affecting either adaptive or innate immune responses (Table 1): (1) 
combined immunodeficiencies (CIDs), (2) well-defined syndromes with 
immunodeficiency, (3) predominantly antibody deficiencies, (4) diseases of immune 
dysregulation, (5) congenital defects of phagocyte number, function, or both,  (6)  
defects  in  innate  immunity,  (7) autoinflammatory  disorders,  and  (8)  complement  
deficiencies [3, 4]. 
 In the last years, advances in molecular genetics and immunology have resulted 
in the identification of a growing number of genes causing primary 
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immunodeficiencies in human subjects and a better understanding of the 
pathophysiology of these disorders. Characterization of the molecular mechanisms of  
PIDs have also facilitated the development of novel diagnostic assays based on analysis 
of the expression of the protein encoded by the PID-specific gene. Pilot newborn 
screening programs for the identification of infants with severe combined 
immunodeficiency have been initiated and appropriate protocols to PID diagnosis and 
management [1]. Furthermore, significant advances have been made in the treatment 
of PIDs based on the use of subcutaneous immunoglobulins, hematopoietic cell 
transplantation from unrelated donors and cord blood, and gene therapy [5].  
 Finally, PID provide a unique opportunity to study the phenotypic and 
functional consequences of a single gene defect for human immunology and this is 
important since there are many differences between mice and human immune system, 
in particular with regard to the NK cell compartment [6]. 
2. MUTATIONS CAUSING PRIMARY IMMUNODEFICIENCIES: 
2.1. Nature of gene defects: 
 Mutations causing primary immunodeficiencies are mostly recessive and often 
require homozygosity to significantly affect immune cells and responses. Since most 
PIDs are inherited in an autosomal recessive pattern, inbreeding has a huge impact on 
PID incidence due to the higher probability for offspring of consanguineous parents to 
be homozygous by descent and to inherit two copies of the same single mutated allele 
than for those born to non-consanguineous parents [7]. However, genetic 
characterization of some PID patients has also shown that de novo mutations can also 
be the cause of disease [8]. 
2.2. Reversion of PID gene defects: 
 Similar to somatic mosaicism due to de novo mutations during embryogenesis, 
mosaicism due to reversions to normal of an inherited mutation have been   
discovered because of milder than expected clinical course and/or presence of both 
phenotypically normal and abnormal cells in vivo and in vitro [9]. A revertant is a 
mutant that has regained, partially or completely, the wild type phenotype by either a 
genetic or a non-genetic mechanism [10]. 
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2.3. Genotypic revertants classification:  
 Genetic revertants fall into two different classes: 
 1) True revertants, which represent a genuine reversal of the original 
mutational event. A so-called back or reverse mutation changes the original 
deleterious mutation either back to the original base or to a third one, thereby 
restoring the amino acid sequence of the wild-type polypeptide. The genetic 
mechanisms involved in reversion are true back mutation (reverse point mutation), 
crossing-over, and gene conversion [11, 12]. 
 2) Revertants resulting from second site mutations or compensatory mutations, 
which take either place inside or outside the mutated gene, without changing the 
nucleotide of the original mutation. Such mutations restore the activity of the mutated 
gene but frequently lead only to partial reversion. The mechanism of second site 
mutations include base pair addition or deletion, suppressor mutation, and 
chromosomal loss or gain [11, 12].  
Table 1: Human primary immunodeficiencies: Classification and affected genes. 
Nº affected genes   
(% total) 
Example 
Reported revertants 
Yes/No Nº genes (% total) Genes 
(1) Combined immunodeficiencies 
98 (31%) JAK3, CD3γ, CD3ε,  Yes 6 (46.1%) 
IL2RG, CD247, 
RAG1, ADA, 
DOCK8, TGFBR1 
(2) Well-defined syndromes with immunodeficiency 
58 (18.4%) LIG1, GATA2 Yes 1 (7.7%) WAS 
(3) Antibody deficiencies 
44 (13.9%) CD19, ICOS, TWEAK Yes 2 (15.4%) FANCA, FANCC 
(4) Diseases of immune dysregulation 
43 (13.6%) CARD11, FAS, ILR10 Yes 1 (7.7%) SH2D1A 
(5) Congenital defects of phagocyte number, function, or  both 
43 (13.6%) IL18, ISG15, IRF8 Yes 1 (7.7%) CD18 
(6) Defects  in  innate  immunity 
22 (6.9%) STAT1, IRAK4, CXCR4 Yes 2 (15.4%) IKBKG, NEMO 
(7) Autoinflammatory  disorders 
19 (6.03%) TRAPS, CIAS1, IL1R No - - 
(8) Complement  deficiencies 
31 (9.84%) Factor B, C2, C3,C4 No - - 
      Total 
        315                                                                                                   13 
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 The spontaneous occurrence of somatic mutations that either reverse or 
compensate the deleterious effects of the original genetic defect is a feature of a 
minimal set of genes affected in PID (Table 1), including those ones for germ-line 
mutations of the adenosine deaminase [13], interleukin-2 receptor γc [14], 
recombination-activating gene 1 [15], the Wiskott–Aldrich syndrome protein [16], 
dedicator of cytokinesis 8 [17], nuclear factor-κB essential modulator (NEMO, or IKKγ) 
[18], TGFBR1 [19], IKBKG [20], SH2D1A [21], leukocyte adhesion integrin CD18 [22], 
FANCA/ FANCC [23-25] and CD247 [26-28] genes. To date, no plausible mechanisms to 
explain why only some PID genes undergo reversion events has been proposed, work 
in this thesis now identifies a potential genetic feature that explains why certain genes 
have higher probabilities to revert gene defects [29]. 
3. T CELL RECEPTOR CHAIN GENE DEFECTS CAUSING PID: 
 Mature T lymphocytes detect the presence of antigens by way of a variable 
surface disulphide-linked heterodimer (either αβ or γδ) termed the T-cell receptor 
(TCR) [30]. In humans, TCR molecules form a complex with two invariant heterodimers 
called CD3γε and CD3δε and a single invariant homodimer termed CD247 (also called 
TCRζ or CD3ζ) [31-34]. These invariant proteins participate in assembly of the whole 
TCR complex, which takes place in the ER before the complex reaches the Golgi 
system, and occurs in a precise and defined order (Figure 1) [35-38]. In fact, only 
correctly assembled receptors can reach the cell surface and pre-assembled TCR 
complexes lacking the CD247 subunit are shunted to degradation [39, 40] (Figure 1). 
TCR assembly and cell surface expression constitute not only a critical landmark during 
thymocyte development, but are also key for the delivery of intracellular signals that 
drive T-cell maturation or apoptosis in the thymus, and T-cell activation, proliferation, 
and effector function or anergy/apoptosis after antigen recognition [41].  
 TCR complex deficiencies in humans are very rare autosomal recessive diseases 
characterized by impaired expression of the TCR at the cell surface and selective T 
lymphopenia and hypofunction [42]. Primary immunodeficiencies affecting total or 
partially T cell receptor complex subunits have been previously described for TCRα [43], 
CD3γ [44-47], CD3 [48-52], CD3ε [49, 53] and CD247 [26-28]. Given that the different 
chains appear to vary in importance for TCR assembly (Figure 1), the lack of each 
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particular subunit produces different degrees of TCR surface expression defects and 
disease severity [54].  
 Mutations in TCRα and the CD3γδε chains that are specifically expressed 
together in T cells affect T, but not B and NK cells. However, the CD247 chain is found 
in other cell types, including Natural Killer (NK) cells [55, 56], where it also acts as a 
signaling molecule for several NK cell receptors as well as Fc receptors [56]. As a 
consequence, work in this thesis shows for the first time how CD247 deficiency affects 
Natural Killer cell receptor biochemistry, function, maturation and development [57]. 
 
Figure 1: Intracellular fate of the TCR and its partial complexes: A schematic diagram of T cell 
receptor assembly illustrating the fate of partially assembled complexes: cis, cis-Golgi, med, 
medial-Golgi; trans, trans-Golgi; TGN, Trans-Golgi network; PM, plasma membrane. 
Redesigned based on [40]. Organelles pictures taken from:  
http://www.somersault1824.com/resources/ 
 
4. NATURAL KILLER CELLS: 
 In the early 1970s, Natural Killer cells were identified as lymphocytes with the 
ability to mediate spontaneous cytotoxic activity against transformed tumor cells 
without any requirement for prior priming [58, 59]. NK cells constitute from 5 to 15% 
of the peripheral blood lymphocyte population [60] and, after T and B cells, are the 
third major lineage of lymphocytes. However, NK cells also reside in a variety of tissues 
including the liver, spleen, bone marrow, decidua, lungs, uterus, thymus, mucosa-
associated lymphoid tissue (MALT) and lymph nodes in humans [61-64]. NK cells 
responses have been traditionally associated with innate immunity, since they can 
release cytotoxic granules containing perforin and granzyme and secrete cytokines 
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such as IFNγ, TNFα, RANTES, MIP1a/B on recognition of virus-infected and tumor cells 
in the absence of prior priming, and because the response was not dependent on 
antigen-specific receptors. NK cells are able to recruit and amplify inflammatory 
responses by regulating the function of other immune system cells such as T cells, 
dendritic cells and macrophages [65-68].  
4.1. Origin, maturation and education of NK cells: 
 Natural Killer originate, together with T and B lymphocytes, from a common 
CD34+ hematopoietic progenitor [69, 70], but also can be generated from myeloid 
progenitors [71]. NK cell development starts in the fetal liver, but after birth, it occurs 
mainly in the bone marrow [72] and minimally in lymph nodes, thymus, gut and liver 
[73-76] in well characterized discrete stages [63, 77].  
 Human peripheral blood NK cells are phenotypically characterized as CD3-
CD56+ and are divided into two main groups: a major NK cell population defined by 
low levels of CD56, but high expression of CD16, called “CD56dim”; and a minor 
“CD56bright” NK population with high levels of CD56 and lacking CD16. Regarding NK cell 
development, after several precursor stages, immature NK cells gain expression of 
CD56, CD94/NKG2A, and several activating receptors including NKp46, NKp30, and 
NKG2D (Figure 2). These cells, called CD56bright NK cells, are highly proliferative, 
capable of producing high amounts of IFNγ, and express IL-7Rα and c-KIT [78-80].  
 In humans, CD56bright NK cells have been hypothesized to give rise to CD56dim 
NK cells [81]. This hypothesis is supported both by the observations that CD56bright NK 
cells have longer telomeres than CD56dim [79], and that in vitro stimulation of CD56bright 
NK cells with IL-2 results in acquisition of CD16 and KIR expression at the same time 
that IL-7R and c-KIT expression is lost [79]. During this process, NK cells also 
downregulate CD56 expression and acquire KIR inhibitory receptors [77, 82]. CD56dim 
NK cells are potently cytotoxic, but have lower proliferative capacity and cytokine 
secretion than CD56bright subpopulation. Although plausible, the idea that CD56dim 
derive from CD56bright in humans has not been established definitely. Indeed, recent 
studies in macaques using genetic barcoding of hematopoietic stem cells strongly 
suggested distinct developmental precursors for both NK cell subpopulations [83]. 
 CD57 and CD62L are, among others, other important developmental NK cell 
markers. CD57 expression is limited to CD56dimCD16+ cells, and absent from CD56bright 
INTRODUCTION 
 
 
31 
 
cc/ 
Dar
NK cells, meanwhile CD62L is first expressed by CD56bright cells and gradually lost 
during the processes of education and differentiation (Figure 2) [84-87].  
Diversity is an essential characteristic of the immune system, and NK cells 
comprise a highly heterogeneous population. High-resolution analyses techniques like 
mass cytometry have shown that somewhere between 6000 to 30,000 phenotypic 
populations exist within an individual [88]. This extensive repertoire flexibility, 
although presumably expanding the range of target cell recognition, if carried to 
excess may decrease the flexibility of the antiviral response and even increase the risk 
of viral infection [89]. 
 
Figure 2: Schematic representation of human NK cell development and terminal 
differentiation: The development of human NK cells from a common lymphoid progenitor over 
NK cell precursors to terminally differentiated NK cells is depicted from left to right. The 
acquisition and loss of indicated surface markers and functional properties for human NK cell 
are indicated by the bars. Protein expression levels are depicted as black for high expression 
and white for no expression, gray indicates intermediate levels.  
4.2. Natural Killer cells, further innate immunity horizon: 
 Recently, novel populations of NK cells that possess adaptive immune features 
such as long-life, qualitatively different responses [90-93] and even antigen specificity 
in the case of mice [94] and macaques [95] NK cells have been described. 
 Although previously NK cells were considered unable to differentiate into 
memory cells, accumulating evidence demonstrates that some NK cells can undergo 
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antigen-specific expansion and differentiation into a long-lived memory subset [96-
100].  
In some mouse models, NK cells are activated after exposure to pathogens, 
antigens, and cytokines, and subsequently differentiate into long-lived memory or 
memory-like NK cells with augmented effector functions in response to a variety of 
secondary stimuli, as compared with naive NK cells [96-98]. It has been demonstrated 
that mouse NK cells bearing the activating Ly49H receptor, which specifically 
recognizes the m157 mouse cytomegalovirus (MCMV) glycoprotein on the infected 
cells [101, 102], undergo activation, expansion, contraction, differentiation into 
memory NK cells, and persist for several months after MCMV infection [98, 103]. These 
MCMV-specific memory NK cells are capable of mounting a recall response and 
provide more effective host protection against rechallenge with MCMV than naive NK 
cells [98].  
Moreover, this phenomenon has also been demonstrated in a rhesus macaque 
model of SIV infection, where NK cells directly target Gag and Env epitopes and 
provide protection for upwards of months [95]. The existence of memory NK cells in 
humans is supported by the specific expansion and lifelong persistence of NKG2Chigh 
NK cells after human cytomegalovirus (HCMV) infection [100, 104-107], or HCMV 
reactivation after superinfection with other viruses such as HIV-1, Hantavirus, 
Chikungunya virus, hepatitis B and C. These “adaptive” NK cells are characterized by a 
longer lifespan and mediate enhanced responses through antibody dependent cell 
cytotoxicity (ADCC) and IFN production.  
4.3. NK cell function: 
 Natural Killer cells fulfill their roles by recognizing sets of specific ligands 
expressed on the target cell with an array of germline-encoded cell surface receptors. 
These receptors are independent of the recombination activating gene enzymes (RAG1 
and 2), that are essential for expression of the T and B cell receptors that require 
rearrangement [108, 109].  
 4.3.1. The inhibition-activation paradigm in Natural Killer cells:  
 Multiple checkpoints have been identified that function to insure an orderly 
progression through an immune response and thereby prevent the generation of self-
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destructive processes. A common theme that has emerged from the study of these 
checkpoints is the requirement for the establishment of discrete thresholds that define 
narrow windows of response. One mechanism to achieve these thresholds is for the 
co-expression of receptors with common ligand binding properties but divergent 
signaling capacities, coupling activating receptors with an inhibitory counterpart, 
thereby setting thresholds for immune cell activation.  
 The activation of Natural Killer cells is regulated by the integration of signals 
from activating and inhibitory receptors expressed on the NK cell after ligation, or not, 
by ligands on the target cell [110, 111]. However, it has been observed that not all NK 
cells respond equally to the same stimulus. The responsiveness of any given NK cell is 
determined during its development in a process referred to as NK cell “licencing” or 
“education” [112, 113].  
NK cell education renders potentially auto-reactive NK cells tolerant to the 
surrounding environment by adjusting the responsiveness of NK cell to ensure self-
tolerance while maintaining the possibility of useful reactivity against potential 
threats. NK cell expressed MHC-specific inhibitory receptors play a major role 
establishing this equilibrium, but signaling from activating receptors is also important, 
suggesting that the integration of signals from both types of receptors is critical. This 
process is still only incompletely understood and a further complication is that NK cell 
responsiveness can be re-set, if for example the MHC environment changes [114, 115].  
Moreover, the inflammatory conditions often associated with infections can 
over-ride the regulated responsiveness of NK cells to modulate their activity [116, 117] 
raising questions such as whether viruses and tumor cells manipulate NK cell 
responsiveness to evade immune-recognition [118, 119]. As knowledge of the 
underlying processes grows, the possibility of modulating NK cell responsiveness for 
therapeutic benefit may also become possible [117, 120]. 
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5. NATURAL KILLER CELL RECEPTORS: 
5.1. Inhibitory receptors: 
 Most of the inhibitory receptors expressed by NK cells recognize classical self 
MHC class I molecules and this is believed to be a key mechanism by which NK cells 
sense perturbations in the self-HLA environment. The majority of NK cells express at 
least one inhibitory receptor, known as KIR, for at least one self-HLA molecule [121]. 
Genes encoding for KIR receptors present multiple alleles and different number of 
genes along the population [122, 123], which generates a broad diversity of inhibitory 
panel of receptors and NK cell reactivity against each host.  
 However, significant proportions of NK cells do not express any self-specific 
inhibitory KIR, and to compensate for this, KIR-negative cells express CD94/NKG2A 
heterodimer that specifically interacts with non-classical HLA-E [124-126]. 
Furthermore, other non-MHC inhibitory receptors including KLRG1, TIGIT, Siclecs, LAIR-
1 or CEACAM1 are present on NK cells. 
 Thus the cellular loss of MHC class I expression due to pathogen infection can 
lead to NK cell activation through the loss of inhibitory signals; this process is known as 
missing self [127]. 
5.2. Activating receptors of NK cells: 
 Natural Killer cells express many activating receptors including Natural 
Cytotoxicity Receptors (NCR), Fc receptors, NKG2 family receptors and others. The 
following section will focus on those receptors that are particularly relevant for the 
work presented in this thesis: 
 5.2.1. Natural Cytotoxicity Receptors: 
 Three NCRs, discovered in the late 1990s, are expressed on human NK cells: 
NKp46 (NCR1; CD335) [128], NKp44 (NCR2; CD336) [129], and NKp30 (NCR3; CD337) 
[130]. They are grouped together as all of them were able to activate NK cells and they 
were important for the killing of tumor cells in vitro. However, despite their similar 
functional abilities, NCRs do not share significant similarities in either their amino acid 
sequence or in their structure. They are type I transmembrane proteins belonging to 
the immunoglobulin superfamily and are composed of one or two extracellular 
immunoglobulin-like domains, which are responsible for ligand binding. In addition, 
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they contain a transmembrane domain with a positive-charged amino acid that can 
interact with signaling adaptor proteins containing immunoreceptor tyrosine-based 
activation motifs (Figure 3). 
 NKp46: This particular receptor was the first NCR to be identified and is the 
most specific marker of NK cells reported so far, regardless of their activation status 
[128, 131]. The NKp46 gene is located on chromosome 19 and encodes two N-terminal 
C2-type Ig domains connected by a hinge region, followed by a stalk domain, a single 
transmembrane domain and a short cytoplasmic region lacking a signaling motif. An 
arginine residue in the NKp46 TM allows its association with the FcR1 and CD247 
signaling modules. 
 NKp30: NKp30 is expressed in all mature NK cells [130]. There are six different 
NKp30 isoforms, generated by alternative splicing after transcription of a single gene 
located in the class III region of the human MHC. Three isoforms possess a C-type Ig 
extracellular domain [132]; meanwhile the most frequent NKp30 isoforms (NKp30 I/c, 
NKp30 II/b and NKp30 III/a) encode V-type extracellular domains and associate 
through a positively charged arginine residue with either FcR1 or CD247 molecules. 
 Surprisingly, although coupled to the same signaling adaptors, engagement of 
each isoform has been shown to trigger different cellular functions and differences in 
the repertoire of isoforms expressed has been linked to prognosis of several cancers, 
autoimmune diseases and reproduction [133-138]. 
 NKp44: The NKp44 receptor is only expressed in activated NK cells [129]. It is 
encoded on chromosome 6 (6p21.1.) and encodes a single extracellular V-type Ig 
domain, connected via a 64-amino acid-long stalk domain, to a single transmembrane 
domain and a short cytoplasmic tail [139, 140] containing an immunoreceptor 
tyrosine-based inhibitory motif, shown to be functional after binding to certain ligands 
[141, 142]. The specific location of a transmembrane sequence lysine residue renders 
NKp44 unable to bind FcR1 or CD247, and instead, it interacts with the DAP12 
signaling dimer. 
 5.2.2. Fc receptors: 
 Fc receptors interact with antibodies or antibody-antigen complexes 
interactions and are expressed on the surface of certain immune cells, including, 
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among others, B lymphocytes, follicular dendritic cells, Natural Killer cells, 
macrophages, neutrophils, eosinophils, basophils, human platelets and mast cells. The 
name, Fc receptor, is derived from their binding to a part of an antibody known as the 
Fc (fragment, crystallizable) region [143, 144]. 
 Upon binding the Fc portion of Ig bound to infected cells or invading 
pathogens, these receptors trigger a wide range of effector functions such as antibody-
dependent cell cytotoxicity by NK cells, mast cell degranulation, antibody secretion, 
and phagocytosis as well as the induction of immunomodulatory signals regulating 
lymphocyte proliferation and antibody secretion, which contribute to the protective 
functions of the immune system. 
 There are several different types of Fc receptors (FcR), which are classified 
based on the type of antibody that they recognize. For example, those that bind the 
most common class of antibody, IgG, are called Fc-gamma receptors (FcγR), those that 
bind IgA are called Fc-alpha receptors (FcαR) and those that bind IgE are called Fc-
epsilon receptors (FcεR). The classes of FcR's are also distinguished by the cells that 
express them (macrophages, granulocytes, natural killer cells, T and B cells), structural 
similarities and the signaling properties of each receptor [145]. 
 Fc-α receptors: Only one Fc receptor belongs to the FcαR subgroup, which is 
called FcαRI (or CD89) [10]. FcαRI is found on the surface of neutrophils, eosinophils, 
monocytes, some macrophages (including Kupffer cells), and some dendritic cells 
[146]. It is composed of two extracellular Ig-like domains, and is a member of both the 
immunoglobulin superfamily and the multi-chain immune recognition receptor (MIRR) 
family [147]. It signals by associating with two FcR1 signaling chains [146]. Another 
receptor can also bind IgA, although it has higher affinity for IgM [148]. This receptor is 
called the Fc-alpha/mu receptor (Fcα/μR) and is a type I transmembrane protein. With 
one Ig-like domain in its extracellular portion, this Fc receptor is also a member of the 
immunoglobulin superfamily [149]. 
 Fc-ε receptors: Two types of FcεR are known: [147] The high-affinity receptor 
FcεRI is a member of the immunoglobulin superfamily (it has two Ig-like domains). 
FcεRI is found on epidermal Langerhans cells, eosinophils, mast cells and basophils 
[150, 151]. As a result of its cellular distribution, this receptor plays a major role in 
controlling allergic responses. FcεRI is also expressed on antigen-presenting cells, and 
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controls the production of important immune mediators called cytokines that promote 
inflammation [152]. The low-affinity receptor FcεRII (CD23) is a C-type lectin molecule. 
FcεRII has multiple functions as a membrane-bound or soluble receptor; it controls B 
cell growth and differentiation and blocks IgE-binding of eosinophils, monocytes, and 
basophils [153]. 
 Fc-γ receptors: All of the Fcγ receptors (FcγR) belong to the immunoglobulin 
superfamily and are the most important Fc receptors for inducing phagocytosis of 
opsonized microbes [147]. This family includes several activating members: FcγRI 
(CD64, present on monocytes and macrophages [154, 155]), FcγRIIA (CD32A, found on 
monocytes, neutrophils and eosinophil platelets), FcγRIIIA (CD16A, expressed on 
mature NK, NKT, subsets of monocyte/macrophages and γ T cells) and FcγRIIIB 
(CD16B, GPI anchored, expressed on neutrophils); and the inhibitory FcγRIIB (CD32B, 
expressed in monocyte, neutrophils, macrophages, basophils, eosinophils, Langerhans 
cells, B-cells, platelets cells and epithelial placenta cells). The genes encoding these 
receptors are located on chromosome 1 [156-158], and display high variability 
between individuals due to single nucleotide polymorphisms (SNP) and copy number 
variation (CNV) [159, 160] that directly affects receptor expression level. As might be 
expected from the importance of these molecules, variability in these receptors has 
been associated with susceptibility to autoimmunity and several infectious diseases 
[161-164]. Moreover, family members differ in their antibody affinities due to their 
different molecular structure [165]. For instance, FcγRI binds to IgG more strongly than 
FcγRII or FcγRIII does. FcγRI also has an extracellular portion composed of three 
immunoglobulin (Ig)-like domains, one more domain than FcγRII or FcγRIII has. This 
property allows FcγRI to bind monomeric IgG molecules, but all Fcγ receptors must 
bind multiple IgG molecules within an immune complex to be activated [166]. 
 The Fc-gamma receptors differ in their affinity for IgG and likewise the different 
IgG subclasses have unique affinities for each of the Fc gamma receptors [167]. These 
interactions are further tuned by specific post-translational modifications at Fc IgG 
portion. The Fc glycan has a heptasaccharide core structure that can be modified by 
the addition of specific residues; these modifications are dynamic and regulate the 
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biological activity of IgGs. Modifications at certain positions of this glycan core are 
critical for proper FcR function (see later for CD16A).  
 Another FcR is expressed on multiple cell types and is similar in structure to 
MHC class I. This receptor also binds IgG and is involved in preservation of this 
antibody [168]. However, since this Fc receptor is also involved in transferring IgG from 
a mother either via the placenta to her fetus or in milk to her suckling infant, it is called 
the neonatal Fc receptor (FcRn) [169, 170]. This receptor is generally thought to play a 
role in the homeostatic regulation of serum IgG levels. 
 Within the spectrum of FcγRs, CD16A (FcγRIIIA) is the low affinity receptor for 
IgG and appears to be specialized for the recognition of multimeric immune 
complexes, such as those found on virus-infected cells, to mediate ADCC, a major 
pathway involved in the clearance of infectious pathogens and tumor cells. Like many 
immune activating receptors, CD16A associates at the cell surface with signaling 
adaptor molecules, in humans, FcεR1γ and CD247 [55, 171-174]. Interestingly, the 
composition of the CD16A receptor complex varies between NK cell subpopulations, in 
particular FcεR1γ expression is silenced epigenetically in adaptive NK cells [90] so that 
in these cells only CD247 is available to pair with CD16A.  
 Stimulation of CD16A on NK cells with ligands results in a rapid rise in [Ca2+], 
and the hydrolysis of membrane phosphoinositides, resulting in the production of both 
inositol 1, 4, 5 triphosphate (IP3) and IP4 [175]. Further cross-linking of the receptor 
augments these responses. Part of the initial [Ca2+], rise depends on mobilization from 
intracellular stores, but sustained [Ca2+] levels require the influx of extracellular 
calcium. NK-cell activation, mediated by CD16A crosslinking, also results in 
transcriptional activation of specific cytokines like IFNγ and TNFα [176]. 
 As already mentioned, N-linked glycan modifications in the IgG-Fc markedly 
affect the affinity of IgG binding to CD16A; and so, the robustness of the cellular 
immune response. For example, binding of human IgG1 to CD16A is highly sensitive to 
the presence of a single N-linked glycosylation site [177], so that deglycosylation 
results in a complete loss of receptor binding [178]. In contrast, Ig-Fc with N-linked 
sugars lacking galactose and terminating instead with GlcNAc moieties, bind CD16A 
with increased affinity [167]. Similarly, glycan modifications to remove a fucose core 
also enhance binding affinity for CD16A [179]. This particular modification has been 
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applied to engineered monoclonal antibody therapies [180]. Importantly, a recent 
report showed that early in Dengue infection a global shift in IgG Fc glycan structure 
occurs, triggering a decrease in antibody fucosylation, and consequently, a higher 
affinity of Ig for CD16A, which has been associated with an increased risk of severe 
disease [181].  
 5.2.3. Clinical relevance of Fc receptors: 
 Since the first successful use of a monoclonal antibody for the treatment of 
lymphoma in 1982, several antibodies, that bind molecules such as CD20, CD22, CD40, 
PD1 and CTLA-4, have been incorporated into standard treatment protocols for cancer. 
Among these therapies, ADCC is emerging as an important function for tumour 
clearance by recognition of therapeutic antibodies by immune cell FcRs [182]. Thus, 
FcRs represent a link between the specificity of the adaptive immune system and the 
powerful cytotoxic effector responses triggered by the innate effector cells. A better 
understanding to allow modulation of the interactions of antibodies with FcRs is one 
obvious strategy to obtain stronger anti-tumor responses and improve monoclonal 
antibody based therapies. In this sense, several groups have succeeded in generating 
antibody variants with increased CD16A affinity by either alanine scanning 
mutagenesis or by computer-based prediction models [183, 184]. 
 5.2.4. Other activating NK cell receptors: 
 2B4: 2B4 (CD244) is a cell surface glycoprotein of the Ig-superfamily structurally 
related to CD2-like molecules [185, 186]. Extracellularly, 2B4 is composed of one 
membrane-distal Ig-V–like domain and one membrane proximal Ig-C2–like domain. 
2B4 has a long, tyrosine-rich cytoplasmic tail. Whereas 2B4 functions mainly as an 
activating receptor on human NK cells [187], on murine NK cells 2B4 has been shown 
to exert both activating and inhibitory effects on the cytotoxic activity of NK cells [188]. 
Upon 2B4 ligation, the SH2-containing adaptor molecule SAP is recruited to 2B4 
cytoplasmic tyrosines, which mediates signal transduction by recruiting the Src-family 
kinase FynT [189], which then phosphorylates downstream signaling molecules, e.g., 
phospholipase C-γ or Vav-1 [190, 191], and trigger NK cell cytotoxic response [192]. 
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6. BIOLOGICAL MEMBRANES AND TRANSMEMBRANE DOMAINS: 
 Cellular membranes are biological membranes that separate the interior of the 
cells from the extracellular environment. Plasma membranes (PM) are composed of a 
mixture of different lipids including phospholipids, glycolipids and sterols.  
 These lipids are amphipathic and thus plasma membranes constitute as 
bilayers; hydrophilic phosphate heads are always arranged so that they are near water 
molecules, intracellular and extracellular fluids, while hydrophobic tails of membrane 
phospholipids are organized to the inner part of the bilayer, keeping away from water 
molecules and generating a hydrophobic environment [193]. 
 Plasma membranes are structurally and functionally asymmetric. In addition to 
lipids, membranes present carbohydrates in the extracellular and are loaded with 
proteins integrally, or partially, embedded in the plasma membrane. In fact, proteins 
account for roughly half the mass of most cellular membranes. Many of these proteins 
are embedded into the membrane and stick out on both sides; these are 
called transmembrane proteins. Furthermore, membrane fluidity allows these 
embedded molecules to flow within the lipid bilayer [193]. 
 The plasma membrane not only regulates the exchange of materials between a 
cell and its surroundings, but also represents an actual physical barrier. Therefore, 
extracellular information has to be transmitted through the membrane into the 
appropriate signal-transducing network. In the particular case of modular receptors, 
this process relies in different proteins connected through their transmembrane 
regions; thus precise receptor connection to appropriate signaling module is essential 
to activate the required cellular response [193]. 
 The lipid bilayer environment strongly limits the range of possible structures for 
transmembrane proteins and the protein portion embedded into the lipid bilayer, 
called the transmembrane domain, reflects the physical properties of the bilayers in 
which it resides. In fact, transmembrane domain sequences have certain particularities 
and can be predicted as they are enriched in aliphatic and hydrophobic residues that 
constitute an  helix [194]. Usually, a helix of 18–21 amino acid length is sufficient to 
span the usual width of a lipid bilayer. 
 The stability of helices is a consequence of the hydrophobic effect and main-
chain hydrogen bonding [195]. The interactions that connect the different subunits of 
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modular receptors are mediated by amino acid side chains exposed to the outer part 
of each subunit helix. 
7. INTEGRATION OF EXTRACELLULAR SIGNALS INTO SIGNALING 
TRANSDUCING NETWORKS AND CELLULAR RESPONSES: 
7.1. Modular design receptors: 
 A large proportion of the receptors that most directly control primary immune 
effector functions: arming and clonal expansion of T and B lymphocytes, activation of 
natural killer cells, and secretion of cytokines and antibodies; belong to a broad class of 
modular activating immune receptors, also known as multi-subunit immune-
recognition receptors (MIRRs). In this sense, ligand-binding and signal-transducing 
functions are contributed by separate protein modules within the receptor complex 
subunits. These receptors share a distinctive molecular architecture in which a broad 
array of ligand-recognition specificities modules assemble non-covalently with one or 
more of a small group of dimeric signal-transducing modules to form functional 
membrane-embedded receptor complexes [31].  
 Because extracellular ligand binding and intracellular signaling functions are 
encoded by separate genes, this modular design creates a platform in which receptors 
can rapidly evolve new ligand specificities, associate with multiple signaling modules, 
and even exchange one signaling pathway for another through relatively small 
changes. In some cases, this functional diversification has clearly been driven by the 
selective pressures of pathogen immune-evasion strategies [196]. The flexibility is 
facilitated by the fact that the molecular interactions governing the assembly of these 
modules into functional receptors are largely restricted to their transmembrane 
domains, where specific residues in the receptor mediate stable interactions with 
residues at the signaling module within the lipid bilayer.  
 While most of the interaction is concentrated at the transmembrane domain, 
in some particular cases there are also some assembly contributions from residues in 
the extracellular or intracellular sequences. For instance, it has been shown directly 
and indirectly that extracellular regions from CD3 subunits can interact and affect the 
assembly and function of the T cell receptor [197-203].  
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7.2. Signaling adaptor molecules:  
 Modular activating immune receptors incorporate one or more of seven 
different dimeric signaling modules, including CD247/CD3ζ/TCRζ, CD3γ, CD3ε, CD79, 
DAP12, DAP10 and FcεR1γ. CD3γδε and CD79 modules associate exclusively with the 
variable T and B cell antigen receptors, respectively, and associate principally through 
interactions between their transmembrane domain. In contrast, CD3ζ, FcεR1γ and 
DAP12 are employed by many receptors from different protein families, and they 
share with the more restricted DAP10 signaling module a lack of folded extracellular 
domains. These are predominantly homodimeric and contain stabilizing intermolecular 
disulfide bonds.  
 In order to trigger cell responses through intracellular signals, these molecules 
have one (for the case of FcεRIγ and DAP12), or several (CD247) immunoreceptor 
tyrosine based activating motifs (ITAM) or a YINM motif for DAP10. ITAMs consist of 
conserved sequences of amino acids that contain two appropriately spaced tyrosines 
separated from a leucine or isoleucine by any two other amino acids. Two of these 
signatures are typically separated by between 6 and 8 amino acids in the tail of the 
molecule (YxxL/Ix6-8YxxL/I, where x denotes non-conserved residues). Following 
receptor engagement, phosphorylation of ITAM tyrosine residues represents one of 
the earliest events in the signaling cascade.  
 The adaptor molecules of particular interest for this thesis are CD247 and 
FcR1 and will be presented in more detail. 
CD247 was first discovered as a disulfide-linked homodimer of two 16kDa non-
glycosylated peptides [204] and contains 8 amino acids in its extracellular domain, 
followed by a single transmembrane domain, and a long 113-115 amino acid 
cytoplasmic tail  [205] containing three ITAM domains. FcεR1γ has a similar structure, 
but a shorter cytoplasmic domain with only one ITAM domain. Comparison of the 
genes for FcεR1γ [206] and CD3ζ [205, 207, 208] chains indicates that they belong to 
the same family and are likely to have arisen by duplication. Both genes are located on 
mouse and human chromosome 1 and show analogous organization of their exons. 
FcεR1γ contains five exons while CD247 contains eight [208]. It has been demonstrated 
that CD247 and FcεR1γ not only form homodimers, but can also interact to assemble 
heterodimers [209]. 
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 7.3. Signal transduction networks: 
 After ligand recognition by activating receptors, Src family kinases are activated 
and phosphorylate ITAM tyrosine residues on signaling modules [210]. This 
phosphorylation triggers the activation and recruitment of protein tyrosine kinases 
such as Syk, or ZAP70 to ITAM signaling modules; or PI3K and Grb2-Vav1, to the YINM 
motif in DAP10. Finally, signaling cascades induce processes involved in cytoskeleton 
reorganization, which is required for NK cell polarization and the release of lytic 
granules, as well as transcription of cytokine and chemokine genes [110, 211]. In 
particular cases, ligand-induced receptor oligomerization is employed as a key factor in 
receptor triggering [212, 213]. 
 In the case of inhibitory receptors, despite considerable diversity in 
extracellular domains, all share Immunoreceptor tyrosine-based inhibitory motif (ITIM) 
in their cytoplasmic tail. Thus, when an inhibitory receptor recognizes its ligand, Src-
family kinases, likely those recruited to the activating receptors, phosphorylate the 
ITIM element and recruit of phosphatases such as SHP-1, SHP-2 or SHIP which 
dephosphorylate proteins implicated in NK cell activation, so blocking NK cell 
activation at an early-stage [211]. Strikingly, this inhibition is a local effect that does 
not affect NK cell response to other activating stimuli [214]. 
7.4. Transmembrane domain mediated interactions between subunits:  
 To date, the best characterized mechanisms of receptor complex assembly are 
those that depend on single interactions in the transmembrane domain (TMD) 
between the different elements of multi-subunit immune-recognition receptors.  
 First described for T cell receptor assembly, association occurs via precise 
interactions between basic and acidic residues localized at precise positions of the 
transmembrane domains of the different subunits in the complex [31]. Formation of 
the appropriate receptor structure is therefore dependent on proper placement of a 
total of three basic and six acidic TM residues (Figure 3). 
 Detailed studies, using site-directed mutagenesis of these residues, 
demonstrated that these specific interactions were necessary, and often sufficient, for 
complex assembly [34], and mutation of these amino-acids led to an assembly defect. 
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 Subsequent studies on the assembly of NK cell receptor complexes, such as 
NKG2D-DAP10 [215] or NKG2C-DAP12 [216], have shown that the association of the 
subunits in these complexes also depends on similar structural arrangements, where 
pairs of aspartic acids in the adaptor molecules interact with either an arginine or 
lysine residue in the receptor TM domain. Indeed, for KIR2DS2 or NKG2D, all residues 
of the receptor TM domain can be mutated to valine or leucine, and the interactions of 
the lysine of KIR2DS2, or the arginine of NKG2D, with aspartic acids in DAP12 and 
DAP10, respectively, are sufficient to maintain the complex formation [217] (Figure 3). 
Therefore, membrane-localized assembly mechanism is relevant for activating 
receptors expressed by many different cell types of hematopoietic origin. In this sense, 
the placement and precise chemical nature of polar residues determine specificity of 
assembly and which signaling module is able to interact with each particular receptor. 
 
 
Figure 3: Assembly and architecture of modular activating immune receptors: Schematic 
representation showing the mechanism for selective assembly of a diverse group of receptors 
and their signaling modules. Key residues involved in receptor association are shown in 
different colors at the particular transmembrane (TM) position. Pink rectangles represent the 
plasma membrane.  
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 However, the mechanisms by which several receptors such as the BCR, CD16A, 
CD64 and FcεR1α associate with their particular signaling modules through the 
transmembrane is still unknown. These molecules lack oppositely charged residues 
suggesting that their assembly with adaptors depends on other modes of other 
interaction. We now define the interacting interface for CD16A and a novel interaction 
mode for Fc receptors that bind FcR1 [218]. 
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OBJECTIVES 
 Modular activating receptors represent a complex scenario in which 
extracellular input signal sensing and intracellular signal transduction rely on at least 
two different elements. CD247 is a highly important signaling module shared with 
different receptors important for both the T and the NK cell compartments. Given the 
opportunity to analyse a new CD247 deficient patient, the phenotype and functional 
consequences of the absence of CD247 for NK cells was investigated, as were the 
genetics underlying patient mutation and the biochemistry of CD247-associated NK 
cell receptors.  
 
 The main objectives of the work presented in this thesis were: 
 
1. Analyse the phenotypic and functional alterations of Natural Killer cells in a 
new primary immunodeficient patient lacking CD247 expression. 
  
2. Investigate the genetics underlying the mutation, specifically the genetic 
reversion, observed in this CD247 deficient patient. 
 
3. Biochemical study of how CD16A NK cell receptor mediates association with 
FcεR1γ and CD247 signaling modules despite the lack of transmembrane arginine or 
lysine residues. 
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NATURAL KILLER CELL HYPORESPONSIVENESS AND IMPAIRED 
DEVELOPMENT IN A CD247-DEFICIENT PATIENT 
 CD247 is a signaling adaptor molecule important for different receptor 
complexes such as the T cell receptor and several NK cell activating receptors. The 
opportunity to study a CD247-deficient PID patient allowed us to detailed analyze for 
the first time the phenotypic and functional consequences of the lack of this protein in 
human NK cells. 
 Here we report a new CD247 patient with a novel inherited mutation in 
homozygosis affecting the CD247 initiation codon, which prevents protein synthesis. 
We observed that CD247 protein was absent in this patient and that protein levels 
were segregated with genotype when mutation carriers in heterozygosis were 
compared with control individuals.  
Surface expression analysis of patient NK cells showed that NKp30 and CD16A 
expression was compromised when this adaptor molecule was absent. Receptor levels 
also correlated with CD247 protein levels among genotypes. However, the expression 
levels of other NK cell receptors, such as NKp46 and 2B4 receptor remained 
comparable to healthy controls.  
 Natural Killer cell function was compromised when cells were activated in 
retargeted lysis experiments stimulating different NK cell receptors. However, in 
response to a receptor independent stimulus, PMA/Ionomycin, NK cell response was 
normal, which confirmed a problem in NK receptor-driven activation in the absence of 
CD247. When the NK cell response was evaluated in other CD3 deficiencies, no 
differences were observed compared to age matched controls, which further support 
that the altered NK cell activation response was specific for CD247 deficiency. 
 Phenotypically, patient NK cells expressed increased levels of CD56, decreased 
levels of KIR2D and an increased proportion of CD94+/NKG2A, suggesting a maturation 
impairment and defective NK cell differentiation. 
 In conclusion, although CD247 deficiency is a rare disease, the identification of 
this new case has allowed a detailed evaluation of the role of CD247 in human NK 
biology.
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ANALYSIS OF THE RECOVERY OF CD247 EXPRESSION IN A PID 
PATIENT: INSIGHTS INTO THE SPONTANEOUS REPAIR OF DEFECTIVE 
GENES 
 T cell receptor complex assembly is a precise and ordered process involving 
eight different components, and is essential for development and function of T cells. In 
fact, in the absence of CD247 protein, TCR is unable to reach cell surface and pre-
assembled complexes are blocked at cis-Golgi and shunted to degradation. 
 Most of the T cells present in CD247-deficient patients are essentially negative 
for cell surface TCR; however, a minimal proportion of revertant cells with normal 
levels of TCR at the plasma membrane can be identified. Close examination of flow 
cytometry analyses of NK and T cells from patient PBMCs revealed phenotypic 
revertants that had recovered intracellular expression of CD247 and normal TCR levels 
at the cell surface, respectively. Further stimulation of patient PBMCs with CD3/CD28 
mAbs showed an expansion of these revertant cells in vitro, supporting that these TCR 
complexes were fully functional. 
 Sequence analysis of CD247 transcripts from cell cultures containing revertant 
cells revealed that CD247 reversion was due to a true back mutation but also a 
compensatory mutation encoding for a CD247 version with an elongated signal 
peptide. Both of which restored gene transcription and were able to support TCR 
assembly and surface expression when introduced into Ma5.8 CD247-deficient cell line 
using lentiviruses. Moreover, a high rate of sequence variation was observed in CD247 
compared to other genes located close on chromosome 1.  
 Reversion phenomena have been reported not only for CD247 deficient 
patients, but also for other genes affected in PID. However, they only represent a small 
proportion of affected genes and it is still unclear why reversion only happens in these 
particular genes. With the data of high variation within CD247 gene as a clue, the 
variation rate of all the PID affected genes that have been reported to suffer somatic 
reversion was analyzed. An increased number of missense variants in the coding 
sequence of these genes, compared to others where no reversion has been found or 
control genes, was found, leading to the hypothesis  that high intrinsic gene variability 
increases the chance of PID gene mutants to revert. 
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Supplementary text: 
Materials and Methods 
 
In vitro culture and expansion of CD3high T cells from CD247- and CD3-deficient 
patients  
PBMC were purified by centrifugation on Ficoll-Hypaque and cultured in RPMI-
1640 medium (Lonza) supplemented with 10% FBS, 10% male AB negative human 
serum (the first week, and later with 5% FBS, 5% Human Serum), 4 mM L-glutamine, 
0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 100U/ml penicillin, 100U/ml 
streptomycin, 10mM Hepes, 50mM -mercaptoethanol (Biowest). Cells were stimulated 
either by culture in 24 well plates coated with anti-CD3 (5ug/ml) and anti-CD28 mAbs 
(10ug/ml) or in the presence of irradiated feeder cells (autologous PBMCs, Daudi and 
RPMI-8866 B cell lines) and PHA (0.5ug/ml). In both cases the cultures were 
supplemented by the addition of 50U/ml recombinant IL-2 (Peprotech). 
The study was conducted according to the principles expressed in the 
Declaration of Helsinki and approved by the Institutional Research Ethics Committees 
of the various hospitals involved. All participants, or their guardians, provided informed 
consent for the collection of samples and subsequent analyses. 
 
Cloning and sequencing of the CD247, CD3, CD16 and FcRI genes 
Total RNA was isolated from cultures of lymphocytes from the patient and a 
healthy relative control using the RNeasy Mini Kit (Qiagen). cDNA synthesis was 
carried out using random hexamer primers and Superscript II (Life Sciences). 
Transcripts for each gene were amplified by PCR using the Expand long template PCR 
system (a mixture of the proof reading polymerase Pwo and Taq Polymerase, Roche) 
and specific primers (Table 1) and purified using the Qiagen QIAquick PCR purification 
kit. Purified PCR products were cloned into pJET 1.2 (CloneJET PCR Cloning Kit) and 
transformed into E. coli DH5α strain. Colonies containing recombinant plasmids, 
identified by restriction digestion, were sequenced (Parque Científico de Madrid and 
GATC Biotech). 
 
CD247 construct generation 
Selected clones of full length wild-type CD247 molecule and the mutant with an 
elongated signal peptide were subcloned from pJET sequencing vector into the 
lentiviral vector pHR-SIN [219] for functional evaluation after lentiviral transduction into 
the CD247-deficient murine T cell hybridoma Ma5.8 [220]. 
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Cell lines  
All cell lines were maintained at 37ºC and 5% CO2 in a humidified incubator 
and split as necessary. Ma5.8 cells (a gift of Drs Hisse M. van Santen and Balbino 
Alarcón, CBMSO, Madrid) were maintained in RPMI medium with 5% foetal calf serum 
(FCS). The 293T packaging cell line was cultured in Dulbecco´s Modified Eagle 
medium (DMEM) with 10% FCS. All media were supplemented with 2mM L-Glutamine, 
0.1mM non essential amino-acids, 10mM HEPES, 1mM sodium pyruvate, 100U/mL 
penicillin, 100U/mL streptomycin, 50μM β-mercaptoethanol. 
 
Lentivirus generation and transduction of Ma5.8 cells 
Lentiviruses were generated by transfection of the 293T cell line with a mixture 
of the plasmids pCMVdR8.74, pMD2G and pHR-SIN [219] containing a specific insert, 
using Lipofectamine Plus (Invitrogen) and Optimen (Gibco). Culture supernatants 
containing lentiviral particles were recovered after 48h, filtered (0.22μm) and stored at -
80ºC. For transduction of Ma5.8 cells, 0.5x106 cells were pelleted, resuspended in 
0.5mL virus containing supernatant with polybrene (Sigma) at 8μg/mL and plated in 
one well of a 24-well plate. This plate was centrifuged 90 min at 800 rpm at RT, 
transferred to an incubator and cultured for 4 to 6 hours at 37ºC, 5% CO2. After this 
time 0.5ml of medium was removed and replaced with 0.5ml fresh medium (RPMI 5% 
FCS). Transduction efficiency was tested by flow cytometry by assay of fluorescence in 
FL-1 channel (CD247-FITC intracellular staining). 
 
CD247 Immunoblotting  
Cells were collected, washed once with PBS and lysed in RIPA lysis buffer (1% 
Triton X-100, 1% DOC, 0.1% SDS, 50mM Tris HCl pH 7.5, 150 mM NaCl, phosphatase 
inhibitors (1mM NaVO3 and NaF, 2mM EDTA) with protease inhibitors (1μM Pepstatin 
A, 1μM Leupeptin) and 0.5mM Iodo-acetamide for 30 min on ice. The lysates were 
centrifuged for 5 min at 13,000rpm to pellet insoluble material and then the protein 
concentration was determined by Bradford Assay. 30g of each lysate were separated 
in 12% SDS reducing polyacrylamide gel electrophoresis followed by transfer to PVDF 
(Immovilon-P, Millipore). Membranes were blocked in 5% dried skimmed milk (1h, 
25ºC), washed three times in 0.05% Tween/TBS and incubated (overnight, 4ºC) with 
rabbit polyclonal anti-CD247 (gift of Prof. B Alarcon) to visualise CD247. The 
membranes were then stripped using Restore Western Blot Stripping buffer (Thermo 
Scientific), re-blocked and developed using mouse monoclonal anti-β-actin (1:15000, 
Sigma) in 0.05% Tween/TBS. 
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Flow cytometry  
PBMCs either freshly isolated, or cultured, were stained with directly labelled 
antibodies specific for CD3, CD56, CD4, CD8 (all from Biolegend) and TCR (BD 
Pharmingen). Ma5.8 cells were stained with PE-labelled mAb specific for V3 
(Pharmingen). For staining, cells were washed and incubated in PBS/0.5% (w/v) 
Bovine serum albumin/1% (v/v) Fetal bovine serum/0.1% Sodium azide buffer (PBA 
buffer) with specific antibodies. All the staining was performed on ice, and the labelled 
cells were maintained on ice until analysis. For intracellular CD247 staining, cells were 
first stained on ice, if necessary, and then washed with PBA and fixed using 2% para-
formaldehyde (PFA). After fixation, cells were washed twice with PBA, and 
resuspended in 0.2% Saponin/PBA (permeabilization buffer) for 15 min on ice in the 
dark. After permeabilization, cells were washed once in permeabilization buffer and 
incubated with CD247-FITC (eBiosciences) antibody in the dark for 30 min on ice, 
washed and resuspended in PBA for analysis. Cells were analysed using either a 
FACSCalibur (BD Biosciences) or Gallios (Beckman Coulter) cytometer. Data were 
analysed with Kaluza Flow Cytometry Analysis. 
 
Gene variation analysis 
Data on genes affected in primary immunodeficiencies where reversion events 
have or have not been described as well as nucleotide variation in control genes 
information was extracted from publicly available 1000 genomes project data 
(http://browser.1000genomes.org), with date 21/09/15. Selected information about 
missense, synonymous and coding variation for each gene, as well as the variation 
information referred to 5´UTR and 3´UTR regions was also extracted. For missense 
and synonymous comparison, variation numbers from database were relativized to 
each gene coding sequence length and plotted as variants described per 1000 base 
pairs for each gene. On the other hand, region analysis was carried out normalising 
variants found at each region to the length of 5´UTR, coding sequence or 3´UTR of 
each gene. Statistical significance was calculated using one way ANOVA test for 
synonymous and missense variation rates and two way ANOVA for variation vs. gene 
region analysis comparing the three different group of genes (*, P<0.05; **, P<0.01; ***, 
P<0.001; n.s. not significant, P>0.05). GDI values were extracted for the indicated 
genes using the GDI server and software (lab.rockefeller.edu/casanova/GDI)[221]. The 
presence or absence of CpG dinucleotides in the vicinity of the indicated genes was 
determined using the UCSC Gene Browser. 
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Supplementary table 1: Primer sequences used for amplification of CD247, CD3, CD16 and FcRI, as well as for sequencing. 
Primers used for PCR and sequencing 
    
Gene Forward primer Reverse primer 
CD247 
cDNA 
GGAGATCTCCACAGTCCTCCACTTCCTG GATCGCGGCCGCATAGGAAGGCTTTAGCATGCC 
CD247 
Exon1 
ACACCCCAAACCCTCAAACCTC AGGAGGGCAGGATTTGAAGGAG 
CD247 
Exon2 
GGTCAGTCAGTCCTAGTGCCA CCTTGCTTTGCTCCTGGATAC 
CD247 
Exon3 
GTTAGTTGCCAAGGAGCGGAG CCTAAACCCAAGACTCTGGCG 
CD247 
Exon4 
CTGTCATGTTAAGGCGTGTTCTC TGGGTCTCCATCTCTTCTCTTG 
CD247 
Exon6 
AGGTTTGGAGCCTTGATTGTG ATTTGCAGCTGGGATGAGAAG 
CD3 
cDNA 
AGTCTAGCTGCTGCACAGGCT CCCCAAATTTGCTCTGATGGC 
CD16A 
cDNA 
GGGGATCCGCCACCATGTGGCAGCTGCTCCTCCC GCGCGGCCGCTCATTTGTCTTGAGGGTCCTTTCTC 
FcRI  
cDNA 
GGGGATCCAGAACGGCCGATCTCCAG GATCGCGGCCGCGAGTCCAGTCCATGGCAGTT 
    
Sequencing primers used for pJET1.2 and pBlueScript vectors 
pJET1.2 CGACTCACTATAGGGAGAGCGGC AAGAACATCGATTTTCCATGGCAG 
M13 GTAAAACGACGGCCAGT GCGGATAACAATTTCACACAGG 
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Supplementary table 2:  Summary of several parameters for each CD247 
gene variant found in cDNA clones sequenced from the CD247 deficient 
patient, a CD16A deficient patient and healthy controls. Gene position 
corresponds to nucleotide base number in full length CD247. CDS denotes 
coding sequence region. 
 
CD247 deficient Patient 
 Gene 
Mutation 
Position 
Gene 
region 
Codon 
Change 
Incidence 
Original 
mutation 
T>C 147 CDS Met>Thr 18/20 
Revertant 
mutation 
C>T 147 CDS Stop>Met 2/20 
Compensatory 
mutation 
A>T 138 CDS No aa>Met 6/20 
Variation 1 C>T 174 CDS Ala>Val 1/20 
Variation 2 C>A 224 CDS Leu>Met 1/20 
Variation 3 G>C 280 CDS Ile>Ile 1/20 
Variation 4 A>G 342 CDS Gln>Arg 1/20 
Variation 5 C>T 346 CDS Gly>Gly 1/20 
Variation 6 A>G 488 CDS Arg>Gly 1/20 
Variation 7 C>T 617 CDS Gln>Stop 1/20 
Variation 8 T>A 921 3´UTR - 1/20 
Variation 9 A>G 1291 3´UTR - 1/20 
Variation 10 C>A 1338 3´UTR - 1/20 
Variation 11 A>G 1444 3´UTR - 1/20 
Variation 12 T>C 1450 3´UTR - 1/20 
Variation 13 A>G 1466 3´UTR - 1/20 
Variation 14 A>T 1481 3´UTR  20/20 
Variation 15 C>T 1527 3´UTR - 1/20 
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CD16A deficient Patient 
 Gene 
Mutation 
Position 
Gene 
region 
Codon 
Change 
Incidence 
Variation 1 A>- 155 CDS Frame shift 1/27 
Variation 2 C>T 174 CDS Ala>Val 2/27 
Variation 3 T>C 237 CDS Leu>Pro 3/27 
Variation 4 T>C 303 CDS Val>Ala 3/27 
Variation 5 A>G 356 CDS Arg>Arg 1/27 
Variation 6 T>C 369 CDS Val>Pro 3/27 
Variation 7 G>T 378 CDS Gly>Val 1/27 
Variation 8 G>T 389 CDS Glu>Stop 2/27 
Variation 9 A>G 498 CDS Lys>Met 1/27 
Variation 10 A>G 573 CDS Gln>Arg 1/27 
Variation 11 A>G 605 CDS Asp>Gly 1/27 
Variation 12 C>T 617 CDS His>His 1/27 
Variation 13 C>T 620 CDS Gln>Stop 1/27 
Variation 14 A>G 704 3´UTR - 1/16 
Variation 15 T>C 725 3´UTR - 1/16 
Variation 16 A>G 740 3´UTR - 1/16 
Variation 17 T>C 804 3´UTR - 1/16 
Variation 18 A>G 824 3´UTR - 1/16 
Variation 19 T>A 835 3´UTR - 1/16 
Variation 20 T>G 871 3´UTR - 1/16 
Variation 21 G>A 881 3´UTR - 1/16 
Variation 22 T>C 882 3´UTR - 1/16 
Variation 23 T>A 912 3´UTR - 1/16 
Variation 24 A>G 997 3´UTR - 2/16 
Variation 25 T>C 1005 3´UTR - 1/16 
Variation 26 T>C 1010 3´UTR - 1/16 
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Variation 27 G>A 1039 3´UTR - 2/16 
Variation 28 G>A 1160 3´UTR - 1/16 
Variation 29 G>A 1176 3´UTR - 1/16 
Variation 30 C>G 1256 3´UTR - 4/16 
Variation 31 G>A 1265 3´UTR - 1/16 
Variation 32 C>G 1333 3´UTR - 1/16 
Variation 33 T>C 1369 3´UTR - 1/16 
Variation 34 G>A 1425 3´UTR - 1/16 
Variation 35 A>G 1456 3´UTR - 1/16 
Variation 36 A>T 1481 3´UTR - 16/16 
Variation 37 A>G 1505 3´UTR - 1/16 
Variation 38 A>G 1561 3´UTR - 1/16 
Variation 39 T>A 1600 3´UTR - 1/16 
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Healthy control 1 
 Gene 
Mutation 
Position 
Gene 
region 
Codon 
Change 
Incidence 
Variation 1 A>G 19 5´UTR - 1/9 
Variation 2 A>G 95 5´UTR - 1/9 
Variation 3 C>T 419 CDS Arg>Trp 1/9 
Variation 4 A>G 492 CDS Lys>Arg 1/9 
Variation 5 T>C 907 3´UTR - 1/9 
Variation 6 T>C 955 3´UTR - 1/9 
Variation 7 T>C 1064 3´UTR - 1/9 
Variation 8 G>A 1125 3´UTR - 1/9 
Variation 9 T>C 1268 3´UTR - 1/9 
Variation 10 A>G 1344 3´UTR - 1/9 
Variation 11 T>C 1427 3´UTR - 1/9 
Variation 12 T>C 1454 3´UTR - 2/9 
Variation 13 A>T 1481 3´UTR - 9/9 
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Healthy Control 2 
 Gene 
Mutation 
Position 
Gene 
region 
Codon 
Change 
Incidence 
Variation 1 A>G 19 5´UTR - 1/10 
Variation 2 G>T 62 5´UTR - 1/10 
Variation 3 G>A 98 5´UTR - 1/10 
Variation 4 A>G 189 CDS Gln>Arg 1/10 
Variation 5 T>C 239 CDS Leu>Pro 1/10 
Variation 6 A>C 314 CDS Cys>Arg 1/10 
Variation 7 C>T 394 CDS Arg>Arg 3/10 
Variation 8 C>G 634 CDS Arg>Gly 1/10 
Variation 9 A>- 660 3´UTR - 2/10 
Variation 10 A>- 673 3´UTR - 1/10 
Variation 11 ->C 714 3´UTR - 1/10 
Variation 12 G>A 827 3´UTR - 1/10 
Variation 13 G>A 984 3´UTR - 1/10 
Variation 14 A>G 987 3´UTR - 1/10 
Variation 15 T>C 1013 3´UTR - 1/10 
Variation 16 G>A 1225 3´UTR - 1/10 
Variation 17 C>T 1245 3´UTR - 1/10 
Variation 18 C>G 1256 3´UTR - 6/10 
Variation 19 G>A 1276 3´UTR - 1/10 
Variation 20 T>C 1391 3´UTR - 1/10 
Variation 21 A>G 1456 3´UTR - 1/10 
Variation 22 A>T 1481 3´UTR - 9/10 
Variation 23 G>A 1484 3´UTR - 1/10 
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Supplementary table 3:  Summary of the number of variants found for some 
specific CD247 exons in clones amplified from genomic DNA isolated from non-
CD247 expressing polymorphonuclear (PMN) cells.  
 
 
 
Gene 
 
 
Exon 
 
Clones 
analyzed 
 
Total 
variants 
Genomic 
CD247 length 
amplified (bp) 
 
Variants per 
1000bp read 
Patients 
somatic 
mutation 
Reversion of 
patients 
mutation 
CD247 1 15 12 405 1,97 1 Yes Present Report 
 2 10 2 401 0,49 1 Yes1 
 3 7 8 263 4,34 - - 
 4 10 16 425 3,76 1 Not analyzed2 
 6 10 0 302 0 - - 
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Supplementary Table 4 
Primary immunodeficiency genes where revertants have been described     
  
Gene 
Name 
Transcript ID Nucleotide ID 
Synonymous 
variants 
Missense 
variants 
5´UTR 
variants 
3´UTR 
variants 
5´UTR 
length 
CDS 
length 
3´UTR 
length 
Gene 
Damage 
Index - GDI 
Phred 
 
CpG 
present 
IL2RG ENST00000374202 NM_000206   25 223 1 4 93 1109 358 0.26766 - 
CD247 ENST00000392122 NM_000734 17 48 14 44 146 491 1050 NA 154 
ADA ENST00000372874 NM_000022   48 152 3 20 129 1091 346 5.60704 83 
WAS ENST00000376701 NM_000377   30 352 2 1 58 1508 278 1.13817 - 
DOCK8 ENST00000432829 NM_203447   250 543 31 45 113 6299 1058 18.28926 101 
TGFBR1 ENST00000374994 NM_004612    52 120 6 421 118 1411 4887 0.58837 142 
IKBKG ENST00000369606 NM_001099857  6 117 1 0 415 1259 605 0.09337 168 
NEMO ENST00000407008 NM_016231  51 75 27 47 213 1583 1759 NA 168 
SH2D1A ENST00000371139 NM_001114937  9 95 7 20 362 377 1775 0.04688 - 
CD18 ENST00000355153 NM_001127491  125 219 18 27 224 2309 430 NA 61 
FANCA ENST00000389301 NM_000135   158 605 3 120 43 4367 1050 7.80511 140 
FANCC ENST00000289081 NM_000136   34 149 9 130 263 1676 2673 3.37227 136 
RAG1 ENST00000299440 NM_000448  83 405 2 97 125 3131 3451 8.76351 - 
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Primary immunodeficiency genes with no revertants described     
  
Gene 
Name 
Transcript ID Nucleotide ID 
Synonymou
s variants 
Missens
e 
variants 
5´UTR 
variant
s 
3´UTR 
variant
s 
5´UTR 
length 
CDS 
length 
3´UTR 
length 
Gene Damage 
Index - GDI 
Phred 
 
CpG present 
RFX5 ENST00000290524 NM_000449 41 105 3 42 222 1850 1546 4.54115 18 
IKBA ENST00000216797 NM_020529  30 51 16 42 111 953 515 NA 111 
IRAK4 ENST00000431837  NM_001145256   19 92 32 93 357 1010 2838 5.19884 41 
ICOS ENST00000316386 NM_012092   17 24 4 61 68 599 1985 1.51225 - 
CD19 ENST00000538922  NM_001178098  50 100 4 20 63 1673 233 2.61413 35 
TNFRSF13B ENST00000261652 NM_012452    32 123 0 30 14 881 482 5.14551 - 
TWEAK ENST00000293825 NM_003809   23 42 11 18 97 749 561 NA 50 
TYK2 ENST00000525621 NM_003331  110 257 24 16 379 3563 320 7.41708 135 
WIPF1 ENST00000392547  NM_003387     54 110 9 95 101 1511 2988 0.96977 122 
STAT3 ENST00000264657 NM_003150   85 185 8 88 219 2309 2425 1.52170 87 
CD3G ENST00000532917 NM_000073   13 45 18 103 81 548 682 10.80204 - 
TNFSF5 ENST00000370629  NM_000074    22 231 1 22 73 785 976 NA - 
RHOH ENST00000381799 NM_001278363  18 36 41 99 737 575 802 0.68348 - 
Lck ENST00000336890 NM_005356   55 114 6 15 139 1529 451 NA 74 
OX40 ENST00000379236 NM_003327     37 39 1 17 42 833 245 NA 52 
IL7RA ENST00000303115 NM_002185   67 216 13 144 104 1379 3134 NA - 
CD3D ENST00000300692 NM_000732    18 49 15 13 138 515 118 0.59015 - 
CD3E ENST00000309424  NM_012099  48 79 24 74 489 1532 1265 1.24983 - 
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TRAF3 ENST00000367025  NM_025228  40 104 21 7 438 1655 191 8.81729 249 
TICAM1 ENST00000248244 NM_182919    58 122 16 16 269 2138 320 6.88939 43 
CD16a ENST00000367969 NM_000569   30 78 13 45 185 872 1349 NA - 
CD16b ENST00000294800 NM_001244753  23 74 32 60 261 809 1324 NA - 
FCER1G ENST00000289902 NM_004106   6 13 3 11 26 260 305 0.90665 - 
CXCR4 ENST00000409817 NM_001008540 34 65 13 20 305 1070 537 0.28802 - 
RPSA ENST00000301821 NM_002295    13 28 13 4 110 887 1076 0.15368 60 
C1QA ENST00000374642 NM_015991    20 42 5 14 86 737 275 0.31014 - 
FCN3 ENST00000270879  NM_003665  26 65 0 4 7 899 253 3.01786 - 
STAT5B ENST00000293328 NM_012448  60 105 3 106 170 2363 2638 1.31577 126 
JAK3 ENST00000458235 NM_000215  186 395 6 131 101 3374 1974 3.69742 160 
ZAP70 ENST00000264972  NM_001079   100 170 21 39 208 1859 383 1.46999 115 
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Control genes     
  
Gene 
Name 
Transcript Nucleotide ID 
Synonymous 
variants 
Missense 
variants 
5´UTR 
variants 
3´UTR 
variants 
5´UTR 
length 
CDS 
length 
3´UTR 
length 
Gene Damage 
Index – GDI 
Phred 
 
CpG 
present 
ACT ENST00000331789 NM_001101     60 58 13 43 85 1127 640 NA 245 
ARPC ENST00000259477 NM_030978   15 13 7 40 87 461 493 NA 93 
ADRA1A ENST00000380586 NM_033303    128 271 16 25 437 1427 440 5.12161 202 
APOA4 ENST00000357780 NM_000482     59 116 2 14 105 1190 165 3.38677 35 
ABHD2 ENST00000352732 NM_152924  43 74 18 308 521 1277 6963 1.24066 59 
CDHR1 ENST00000372117 NM_033100   91 231 5 108 127 2579 4082 5.36670 85 
CCT6A ENST00000275603 NM_001762   39 74 14 30 165 1595 922 3.94523 105 
COL9A1 ENST00000357250 NM_001851   109 270 10 71 160 2765 880 17.93014 61 
CYP1A1 ENST00000395048 NM_000499 36 151 3 42 123 1538 947 8.23125 - 
DHX8 ENST00000262415 NM_004941   79 131 7 57 122 3662 485 1.39801 28 
DCTN1 ENST00000361874 NM_004082   98 254 11 17 319 3836 363 4.54937 - 
E2F1 ENST00000343380 NM_005225  39 66 3 38 141 1313 1268 2.63160 142 
ANGPTL1 ENST00000234816 NM_004673          40 94 17 51 477 1475 1603 1.77414 - 
KDELC2 ENST00000323468 NM_153705   28 75 4 72 67 1523 2721 3.29002 101 
HSP90AA1 ENST00000334701 NM_001017963  90 142 16 45 346 2564 977 2.04609 157 
HCAR1 ENST00000432564 NM_032554      36 64 4 77 244 1040 1693 3.33717 - 
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IFNAR2 ENST00000382241 NM_207585     46 102 18 61 360 1547 1013 4.30687 94 
LTBP1 ENST00000418533 NM_001166264      146 348 4 47 142 4061 979 5.77162 164 
DUSP1 ENST00000239223 NM_004417    27 45 13 26 249 1103 688 3.19307 172 
ACAD9 ENST00000308982 NM_014049   53 102 11 28 203 1865 540 2.84303 55 
MYO15A ENST00000205890 NM_016239    279 620 16 26 339 10592 945 16.09179 275 
NFATC1 ENST00000253506 NM_001278669    149 188 16 98 454 2831 1746 8.00523 544 
OTUB1 ENST00000538426 NM_017670   24 25 2 46 605 815 890 2.06462 85 
PRDX1 ENST00000262746 NM_002574   15 41 20 15 342 599 322 0.75000 64 
PSMA1 ENST00000396394 NM_002786    27 24 18 6 147 791 343 0.79430 52 
TYRO3 ENST00000263798 NM_006293   96 181 1 31 237 2672 1092 7.27014 20 
RYR1 ENST00000355481 NM_001042723    675 1785 10 7 131 15101 144 8.51518 320 
ANKS1A ENST00000360359 NM_015245    110 200 10 104 143 3404 2808 5.26551 61 
TSPAN1 ENST00000372003 NM_005727   16 46 13 19 475 725 439 1.21738 - 
VAMP1 ENST00000396308 NM_014231    6 10 22 21 369 356 2245 0.16428 76 
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TRANSMEMBRANE FEATURES GOVERNING FC RECEPTOR CD16A 
ASSEMBLY WITH CD16A SIGNALING ADAPTOR MOLECULES 
 Multicomponent immune receptors are those where ligand binding and 
intracellular signal transduction are mediated by different elements. The physical 
coupling of both elements is highly important and takes place through their 
transmembrane (TM) domains. 
Previously described interactions for other receptor complexes are based on a 
single principle: assembly between complex subunits relies on single interactions at 
precise positions between lysine or arginine residues in the receptor and pairs of 
aspartic acid, present in the signaling dimer. However, the transmembrane domain 
sequence of the CD16A NK cell receptor also presents an aspartic acid and yet clearly 
associates with CD247 since CD16A expression was markedly reduced, in a CD247-
genotype dependent manner in the CD247-deficient patient and family NK cells. 
Thus, in this article, the biochemistry of the interaction between CD16A and 
CD247 or FcεR1γ was analyzed in detail to better understand their transmembrane 
association. Initial in vitro transcription, translation and assembly of complexes using 
multiple CD16A-TM mutants identified the residues involved in this association, which 
was further supported by the observation of membrane expression defects when 
these mutants were expressed in NK cell lines. Molecular modeling corroborated that 
all interacting residues were located within the same receptor interface. In contrast to 
the well-established “complementary-charge” model, the CD16A transmembrane acid 
acts principally in protein quality control and complex association depends on multiple 
polar and aromatic residues along the entire length of CD16A transmembrane domain. 
 These observations were extended to other Fc receptors that also lack 
transmembrane positively charge residues and bind same signaling dimer, FcεR1γ, and 
similar interacting interfaces were identified. 
 To sum up, all these results show a novel mode of complex formation between 
immune receptor and signaling adaptor molecules that underlies the ability of the 
CD247 signaling adaptor molecule to interact with many receptors by different 
mechanisms.
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RESULTS 
NKp46 AND NKp30 SPLICE VARIANTS PLASMA MEMBRANE EXPRESSION 
Given the observations regarding surface expression of the NKp30 and NKp46 
NK cell receptors in the CD247 deficient patient; we further investigated the 
requirements for both receptors to associate with adaptor molecules to reach the 
plasma membrane in a controlled transfection system in vitro. 
NKp30 expression was significantly decreased in the CD247 deficient patient 
and relatives, even in individuals heterozygous for the CD247 inactivating mutation. 
This observation was surprising since this receptor would be expected to associate 
with the Fc1R adaptor molecule to maintain some level of surface expression [222]. 
Therefore, the levels of NKp30 mRNA expression were assessed. Total levels of NKp30 
mRNA were normal (data not shown).  
Due to alternative splicing, three isoforms of the NKp30 gene with differences 
in the cytoplasmic tails are expressed in healthy individuals. Analysis of the expressed 
repertoire of these variants by RT-qPCR showed that the splice variant NKp30 II/b was 
the dominant isoform expressed in this family (data not shown). This observation is 
consistent with previous data showing that the NKp30 II/b isoform is the most 
frequently expressed in healthy individuals [133].  
Transfection of NKp30 isoforms constructs alone showed that the NKp30 I/c 
and NKp30 III/a isoforms can be stably expressed at the plasma membrane themselves 
despite the presence of an arginine residue at their transmembrane domain. NKp30 
staining was increased when NKp30 III/a was co-transfected with CD247, while no 
variation was observed for NKp30 I/c when signaling adaptor molecules were co-
expressed. In contrast, NKp30 II/b was barely expressed at the cell surface when 
transfected alone (Figure 4A).  
Strikingly, in transient transfection experiments co-expression of the “b” 
isoform with CD247 led to significantly enhanced levels of cell surface NKp30 
compared to co-expression with FcR (Figure 4A). This marked preference of the 
NKp30 II/b isoform to associate with CD247 rather than Fc1R explains the marked 
loss of NKp30 expression by the NK cells of family members with either partial or 
complete loss of CD247 expression. 
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In contrast to the observations made for the isoform I/c and III/a, where the 
presence of arginine residue at the plasma membrane did not seem to affect stable 
expression at the cell surface; the NKp30 II/b transmembrane arginine residues was 
important since a leucine for arginine substitution allowed receptor surface expression 
(Figure 4B), indicating that the exposure of this charged residue at NKp30 II/b 
interfered with membrane localization. 
  
Figure 4: NKp46 and NKp30 splice variants association with signaling adaptor molecules: 
293T cells were transiently transfected with the indicated combination of plasmids and then 
analysed by flow cytometry for receptor cell surface expression. The percentage of cells 
expressing NKp30 or NKp46 on cell surface and the geometric mean fluorescence intensity of 
staining are shown. Data represent the mean ± SD of at least three independent experiments. 
Statistical significance was determined using one-way ANOVA-Tukey´s multiple comparison 
test (*, P<0.05; **, P<0.01; ***, P<0.001). 
NKp46 expression on NK cells was comparable in all the patients, independent 
of their genotypes; suggesting that CD247 was not required for surface expression of 
NKp46. In agreement with this observation, transfection of 293T cells also showed that 
NKp46 was able to reach the plasma membrane alone, independently of either 
signaling adaptor molecule (Figure 4C), and no increase was observed when co-
transfected with either Fcε1Rγ or CD247. This result is consistent with the observation 
that transfection of an NKp46 cDNA, in the absence of any adaptor molecule, was 
sufficient for surface expression of the NKp46 protein [223], even though NKp46, like 
CD16A, has been reported to associate with both CD247 and Fcε1Rγ [223].   
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MATERIALS AND METHODS 
Cell lines 
 The 293T cell line was maintained at 37°C and 5% CO2 in a humidified 
incubator and split as necessary and cultivated in Dulbecco´s Modified Eagle medium 
(DMEM) with 10% foetal calf serum (FCS). Media were supplemented with 2 mM L-
Glutamine, 0.1 mM sodium pyruvate, 100 U/mL penicillin, 100 U/mL streptomycin. 
 
Construct generation 
 cDNA clones corresponding to each NKp30 isoform as well as NKp46 were 
amplified by PCR using specific pairs of primers and cloned into the pEGFPN1 vector 
(Clontech) to be expressed as a fusion with EGFP. Full length cDNA clones of CD247 
and FcR1 were amplified by PCR and then cloned into the pHRSin expression vector 
[219]. The integrity of all plasmids was verified by sequence analysis. The arginine to 
leucine mutation at NKp30 II/b transmembrane domain was generated by PCR. 
Table 2: List of primers used for construct generation. 
       Gene Primer 5´→ 3´ 
       NKp30 I/c  F:   TTTCCTCCATGACCACCGG 
R:   TTCCCATGTGACAGTGGCATT 
       NKp30 II/b  F:   TTTCCTCCATGACCACCGG 
R:   CGGAGAGAGTAGATTTGGCATATT 
       NKp30 II/b R>L mutant F:   GTCCTCCTCCTTCTGGCTGGATTCTATG 
R:   CATAGAATCCAGCCAGAAGGAGGAGGAC 
       NKp30 III/a F:   TTTCCTCCATGACCACCGG 
R:   GGACCTTTCCAGGTCAGACATT 
       NKp46 F:   GCCAAGCTTGCCACCATGTCTTC 
R:   GCGGTACCCCAAGAGTCTGTGTG 
       CD247 F:   GCCAAGCTTGCCACCATGAAGTGGAAGGCGCTTTTC 
R:   GCGGTACCCGAGGGGGCAGGGCCTG 
       FcR1 F:   GGGGATCCAGAACGGCCCGATCTCCAG 
R:   GATCGCGGCCGCGAGTCCAGTCCATGGCAGTT 
 
Transient transfection 
 105 293T cells were transfected with a plasmid driving receptor expression in 
the presence or absence of plasmids encoding the Fc1R or CD247 signaling adaptor 
molecules using the jetPEI® transfection reagent. 24 hours after transfection, cells 
were harvested and cell surface receptor expression was evaluated by flow cytometry. 
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Flow cytometry 
 293T cells were harvested, washed and incubated in PBS/0.5% (w/v) bovine 
serum albumin/1% (v/v) foetal bovine serum/0.1% sodium azide buffer (PBA buffer) 
and stained using purified NKp30 (R&D, MAB1849) or NKp46 (R&D, MAB1850) specific 
mAbs, followed by anti-mouse-Ig coupled to PE (Dako Cytomation) for 30 min at 4ºC. 
Cells were analysed using FACSCalibur (BD Biosciences) cytometer. Data were analysed 
with FlowJo and Kaluza Flow Cytometry Analysis programs. 
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Primary immunodeficiencies are a diverse group of rare diseases affecting the 
immune system. They are generally single gene disorders, either inherited or due to de 
novo mutations during embryogenesis, that affect specific components of the immune 
system. Detailed analysis of samples from these patients provides a unique 
opportunity to study the consequences of the lack of a single protein in human 
immune biology [6]. In particular, CD247 deficiency is an extremely rare disease and 
the identification and characterisation of this new case has stimulated detailed 
evaluation, and re-evaluation, of several aspects of the biology of this key signaling 
adaptor molecule in the human immune system. 
CD247 DEFICIENCY: IMMUNE SYSTEM ALTERATIONS 
To date, three patients with mutations affecting the function of CD247 have 
been described. In the first two patients, T cell alterations were analysed in detail, but 
little work was done on the NK cells from these patients. Therefore, the key objective 
of the experiments done on the third patient was to analyse in detail the effects of the 
lack of CD247 on NK cells. 
Analyses of surface expression of a panel of NK cell receptors revealed 
dramatic decreases in CD16A and NKp30 expression at the cell surface. This 
observation was expected because these receptors are known to associate with CD247 
[56, 222, 224]. Interestingly, however, surface expression of another CD247-associated 
receptor, NKp46 [223], did not vary in the absence of this signaling molecule. 
Subsequent in vitro experiments revealed that this surprising result was because 
NKp46 is able to reach the cell surface even in the absence of signaling adapter 
molecules despite the presence of an exposed arginine residue. As expected, 
membrane expression of the 2B4 receptor that does not associate with CD247 did not 
differ between patient and controls. Several splice variants of NKp30 have been 
described [132] and qPCR analysis of NKp30 isoform expression in the CD247-deficient 
patient showed that NKp30b was the dominant isoform expressed in vivo in this 
individual. In vitro experiments involving transfection of specific NK cell receptors, 
alone or in combination with adaptor molecules, corroborated that NKp30b and 
CD16A have to complex with the signaling modules to be stably expressed at the cell 
surface. In contrast, NKp46, NKp30a and NKp30c did not require association with 
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adaptor molecules to be expressed at the plasma membrane.  
NKp30 splice variants are highly similar and only differ in their cytoplasmic tail 
sequence. Further experiments studying cytoplasmic tail mutants of each NKp30 
isoform showed that these sequences limit or favour membrane expression (data not 
shown, in preparation). In the case of NKp30 II/b, an arginine to leucine mutation in 
the transmembrane domain made this receptor independent of adaptor molecule 
association for cell surface expression, indicating that this charged residue also 
controls membrane stability and has to be shielded for expression at the cell surface. 
Therefore, in vitro experiments and analyses of CD247 deficient NK cells indicate that 
membrane targeting and localization of NK cell receptors are tightly regulated by 
transmembrane and cytosolic determinants specific for each particular receptor. 
In functional experiments, NK cell function after ligation of specific receptors 
was also evaluated and showed that CD247-partner receptors driven function was 
compromised in a genotype-dependent manner. Surprisingly, the response of the NK 
cell receptor 2B4 that does not signal through CD247 was also impaired, suggesting 
that patient NK cells are hyporesponsive, likely due to alterations in maturation 
process.  
Since the in vitro transfection and IVT experiments showed that CD16A had no 
clear signaling module preference, associating equally well with either FcR1 or 
CD247 [218], it was expected that membrane expression should be maintained with 
FcR1 even in the absence of CD247, but that was not the case. This result may 
indicate that FcεR1γ is preferentially recruited by other receptors or simply that FcR1 
expression is insufficient to sustain membrane expression of CD16, NKp30 II/b and 
NKp46. It has previously been shown that FcεR1γ protein abundance, even in NK cells 
from healthy individuals, is limited compared to CD247 [225]. 
Similarly, in all of the CD247 deficient patients reported, the absence of such a 
key adaptor molecule also caused severe defects in T cell receptor expression at the 
cell surface. Indeed, T cell receptor stimulated responses, analysed in either primary or 
immortalised T cells, such as proliferation, signaling cascade protein phosphorylation, 
activation markers, etc., were markedly impaired [26-28], even though the CD3 
subunits still provide four ITAM motifs to the TCR complex. Thus the functional 
impairment is due to the key role of CD247 in TCR assembly, essential for membrane 
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expression, and not to the partial loss of ITAM signaling within the complex.  
Hematopoietic lineages and cellular differentiation have been widely studied in 
mice. However, for obvious reasons, much less is known about cellular development 
and differentiation in humans. CD247 has been shown to play a key role in T cell 
development and education in thymus [41], thus the opportunity to analyse NK cells 
from a CD247 deficient patient provided an opportunity to study the effect of the 
absence of CD247 on NK cell development. The analysis of peripheral blood NK cells in 
the CD247 deficient patient revealed an alteration in the normal distribution of 
circulating CD56bright and CD56dim NK cell populations so that the proportion of 
CD56bright NK cells was increased. However, this increase in circulating CD56bright NK 
cells was noted not only in the CD247 deficient patient, but also in all the CD3 deficient 
patients examined, and was statistically significant even after removal of an outlier 
sample. Thus these data suggest that the increased frequency of CD56bright NK cells 
circulating in the peripheral blood of these immunodeficient patients is related to the 
absence of fully functional T cells in these individuals rather than a specific defect in 
CD247 function. Interestingly, a marked increase in the frequency of CD56bright NK cells 
was also reported to be a feature of a case of X-linked severe combined 
immunodeficiency, secondary to a γc defect, with Omenn syndrome-like symptoms 
[226].  
It is fascinating how a T cell compartment defect [28] has an indirect effect on 
NK cells. Indeed, it seems probable that all immunodeficiencies causing TCR defects 
will affect the contribution of T cells to NK cell growth, maturation and development. 
IL2 has been reported to be produced mainly by CD4 T cells, allowing lymphocyte 
proliferation [227]. The addition of recombinant IL2 to mixed lymphocyte cultures for 
NK cell expansion rescues NK cell growth and expansion [57], which corroborates the 
importance of a fully functional T cell compartment able to secrete IL2 for proper NK 
cell development, maturation and responsiveness. 
Finally, alterations in CD247 protein expression have been reported in other, 
different contexts. Populations of T cells that have lost CD247 expression can be found 
in systemic lupus erythematosus (SLE), rheumatoid arthritis, cancer, and infectious 
diseases [228-231]. In contrast, it has been recently described that CD247 protein is 
upregulated in leukaemia patients [232, 233] with increased T cell response and 
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cytokine production by T cells, that lead to inflammation [234]. However, the 
consequences of the somatic appearance of a population that lack CD247 are 
completely different compared to an inherited CD247 defect that inhibits T cell 
repertoire formation and enhances susceptibility to infection since birth. 
SPONTANEOUS REVERSION OF PATIENT CD247 MUTATION 
It has been known for many years that the mutation rate varies across the 
genome [235]. Variation in mutation rate has not only clear implications for 
evolutionary biology, but also underexplored implications for our understanding of 
hereditary diseases and cancer. 
De novo mutations have been widely shown to be a major cause of severe 
early-onset genetic disorders such as intellectual disability, autism spectrum disorder, 
and other developmental diseases. However, when genetic defects are inherited, de 
novo mutation phenomena can also, albeit infrequently, provoke the opposite effect; 
ie. spontaneous mutations can generate a nucleotide change at the same position as 
the genetic defect and so revert the inherited mutation. 
The occurrence of de novo mutations can be related to cell-specific properties. 
Mutational hotspots for genomic rearrangements are largely determined by the 
underlying genomic architecture associated with chromatin state, transcriptional 
status, and gene expression levels. Briefly, areas with open chromatin, high replication 
transitions, and high frequencies of CpG dinucleotides have been shown to be more 
likely to display elevated mutability. Thus, it can be expected that the higher the 
intrinsic mutation rate, the more likely a locus is to have a genetic defect, but also 
reversion. 
The molecular bases and factors influencing de novo mutations have been 
widely studied by different approaches and models. Some of the explanations of 
variation patterns have clear mechanistic bases, but much of the rate variation 
remains unexplained.  
The analysis of non-coding DNA, such as the CpG islands, has been shown to 
affect genetic variation rates in mammals, with up to 15 fold increase over normal 
variation rate [236-239], mainly because of uncorrected C to T transitions after the 
deamination of methylated cytosine bases (which are unstable) to thymidine [240]. 
Indeed, we observed a higher frequency of these dinucleotides in genes where 
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individuals with defect reversion have been reported. 
Genome transcription levels and packaging have also been described to affect 
mutation rate since DNA becomes more exposed as it becomes unwound from the 
nucleosomes and as it becomes single stranded [241]. However, this area is somewhat 
controversial. Some studies support the idea that transcriptionally active DNA will be 
more prone to nucleotide mistakes during DNA replication so giving rise to de novo 
mutations as a result of the erroneous incorporation of nucleotides by DNA 
polymerases [242], and escape of proofreading function of polymerase subunit or 
either restoration by the mismatch repair pathway (MMR) [243]. Transcriptionally 
active DNA can be also more exposed to potential mutagens. On the other hand, 
transcriptionally active regions may be repaired at higher rates than inactive parts of 
the genome, and proliferating cells may display higher repair activities than quiescent 
cells. This might arise from a tight coupling of the repair process with both 
transcription and replication, all these processes taking place on the nuclear matrix. 
Repair activities differ greatly among species, and there is a good correlation between 
life span and repair among mammals. It is predicted that genes that are 
transcriptionally active in germ-cell lineages have a lower mutation rate than bulk 
DNA, a circumstance that is expected to be reflected in evolution [244]. It is not clear 
whether CD247 transcription levels during T and NK cell differentiation may have an 
effect on mutation rate affecting our particular case of CD247 deficiency. Synthesis of 
CD247 is known to be the rate-limiting component of T cell receptor complex 
assembly, but how this relates to transcription of CD247 in T cells is unclear. When 
CD247 transcripts from healthy controls were cloned and sequenced, a high variation 
compared to consensus sequence and other genes localized in the same chromosome 
was observed. Moreover, this phenomenon seemed specific to CD247, as such 
variation was not a feature of other CD3 gene transcripts even in patients suffering 
deficiencies affecting these CD3 genes. 
Although the molecular basis of the putative mutability of CD247 is unknown it 
is interesting to note that the CD247 gene has been reported to display a particular 
pattern of polymorphism so that while most SNPs in the human genome are biallelic; 
some genes, including CD247, have triallelic SNPs. The factors underlying this 
phenomenon are not clear, but it has been suggested that in these genes the 
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occurrence of one mutation can induce the simultaneous production of two new 
mutations within the same individual on the same genetic background [245], which 
support the idea of a high mutational state for CD247 and so an elevated possibility of 
CD247 deficient patients to revert their gene defects. 
The process by which newly synthesized proteins are efficiently targeted to the 
translocation machinery of the endoplasmic reticulum (ER) is presumed to begin with 
the emergence from the ribosome of a signal sequence. Typically, signal sequences are 
cleaved from the protein during or immediately after translocation to the ER lumen. 
Therefore, changes such as additions or deletions that may affect the signal cleavage 
site can influence the interaction of newly transcribed molecules with various 
components of the ER translocation system [246]. Actually, that mRNAs possess 
sequences that alter protein translation was postulated some time ago [247]. 
In eukaryotic cells, the synthesis of membrane proteins destined for the plasma 
membrane, ER or any other membrane-bound compartment begins on cytosolic 
ribosomes. After a short segment of protein has been synthesized, the ribosome, 
mRNA and nascent protein chain associate with the ER, where the rest of the protein is 
made and simultaneously inserted into the membrane. This phenomenon was first 
characterised by Günter Blobel, David Sabatini and Bernhard Dobberstein in the 1970s. 
These scientists proposed that there is a binding factor, lately called N terminal signal 
sequence, that recognizes the emerging protein chain and can dock the ribosome at 
the ER membrane [247]. 
Analysis of the most frequent somatic mutation found in revertant T cells 
from this new patient showed that this variant compensated for the loss of the normal 
initiation codon by a point mutation 3 codons upstream that created a new ATG codon 
and lengthened the signal peptide by three amino acids (Asp-Lys-Thr). Some signal 
peptide-prediction programs (SOSUIsignal) indicated that this new sequence would 
function as a signal peptide, while others (SignalP-4.1) suggested that this longer 
sequence would not be an efficient signal peptide. Transfection of Ma5.8 cells with 
wild-type CD247 and the mutant showed that the mutant could restore surface TCR 
expression, but less efficiently than wild-type CD247 (Figure 5), consistent with a 
possible lower efficiency of mutant CD247 protein translocation into the ER. Here it is 
interesting to note that previous analyses of revertant T cells in CD247 deficient 
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patients had shown that although these T cells had recovered TCR expression, they 
were still not fully functional in that phosphorylation of ZAP70 after TCR stimulation 
was defective [26]. Interestingly, analysis of Ma5.8 cells transduced to express the 
essentially TM-only domain of CD247 described by Rieux-Laucat et al, also led to 
restoration of cell surface TCR expression (data not shown), but again at lower levels 
than those achieved by expression of the wild-type CD247 molecule. This observation 
is striking, because the patient in whom this mutation was identified suffered a 
marked T-lymphopaenia [26], thus these data suggest that the failure to detect 
circulating CD3 positive T cells in this patient is due to a defect in signaling, possibly at 
thymus selection state, rather than simply a defect in assembly and expression of the 
TCR complex. 
These data also emphasise that mutations in different locations of CD247 can 
produce very different consequences depending on the role and function of the 
specific protein segment affected. In fact, it has been previously reported that there 
are functional differences even between closely related regions of the CD247 molecule 
[248]. 
Finally, it is important to highlight that the possibilities of detecting genetic 
reversion events that repair gene defects depends on the selective advantage of the 
gain of function after reconstitution in revertant cells (Figure 5). This determines in 
vivo expansion, that, in turn, depends on the magnitude and importance of the 
particular gene function affected initially, but in some cases (eg WAS) can lead to 
disease “cure”.  
In fact, a closer look at the genes where reversion has been described, showed 
that many genes within this group are key for immune development and host defence, 
such as IL2RG, CD247, RAG, etc. It is possible that there may be more PID in which 
reversion events take place but that these have not been detected due to their 
particular effect on cell surveillance, proliferation or function and thus clinical 
detection. For example, the CD40 ligand gene affected in Hyper-IgM syndrome shows 
a high mutation rate, but no reversion events have been described even though more 
than one hundred patients have been described. However for this reversion to be 
visible it would have to occur in a follicular dendritic cell that interacts with a B cell 
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that makes an antibody that is potently selected for in vivo, despite the IVIG treatment 
that is generally given to these patients. It’s obvious that it’s much more unlikely that 
any such reversion event would be detected compared to a mutation that directly 
affects the ability of a given lymphocyte to expand. 
 
Figure 5: Illustration of the proliferation and gain of functionality of revertant T cells: 
Schematic representation of the consequences of the different CD247 gene reversion in 
contrast to mutant cells fate. Cells are colour-matched with CD247 sequences. Patient 
mutation affects CD247 initiation codon and avoids protein expression. Patient CD247 gene 
reverts due to a true back mutation and a compensatory mutation; both of which allow TCR 
assembly and surface expression, though compensatory mutant cells had lower levels of TCR 
at the cell surface. Revertants selective advantage triggers an expansion of these cells in 
patient T cell cultures containing revertants. Transcripts initiation codons are underlined and 
patient mutation and revertant mutations are highlighted in bold. 
INSIGHTS INTO THE BIOCHEMISTRY OF MODULAR RECEPTORS 
Between 20% and 30% of the proteome of eukaryotic organisms is predicted to 
comprise integral membrane proteins [249]. These are typically synthesised at the 
endoplasmic reticulum (ER), where transmembrane domains (TMDs) are integrated 
into the lipid bilayer and cytoplasmic/luminal domains undergo the folding steps and 
post-translational modifications necessary to achieve their native structure [250]. 
From the ER, correctly folded proteins are incorporated intro transport vesicles from 
delivery to the cis-Golgi and subsequently to the trans-Golgi network, from where they 
are sorted to their site of function [251]. In contrast, proteins that fail to attain the 
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correct conformation are prevented from moving along the secretory pathway by a 
series of quality control checkpoints, including those at the ER, Golgi apparatus and 
plasma membrane [252-255]. 
Unlike sorting signals in cytosolic domains, transmembrane domain sorting 
determinants are not conserved amino acid sequences but rather depend on physical 
properties such as the length and hydrophicity of the transmembrane span. 
A helical bundle of completely hydrophobic residues is a very limited structure 
with which to accomplish transmembrane functions, so it is not surprising that more 
polar groups are found, including Q, N, H, D, E, R, and K. Many of these have been 
implicated in proton or electron transport or in binding prosthetic groups. When these 
groups are placed in a low dielectric environment, they are likely to be in their 
uncharged forms, but will nonetheless remain strongly polar [195].  
Close inspection of the NMR CD247 dimer structure [256], showed that in this 
situation, the aspartic acid side chains from each CD247 molecules face one another, 
and are not exposed to the hydrophobic environment of the bilayer. In this scenario 
the CD247 TM domains are in a state of partial ionization [257]. Results obtained in 
dimerization experiments using CD247 TM mutants suggest that dimerization only 
requires a combination of at least one acidic residue and a polar residue at position 6 
in the two strands, and there may be one charged residue and the other one 
protonated [256]. 
In fact, when molecular modelling studies assembling the CD247 dimer 
together with the CD16A receptor were carried out, only the condition in which one 
aspartic acid of the CD247 dimer pair was charged enabled the association with 
CD16A, strongly suggesting that one charged and one protonated and so with polar 
behaviour aspartic acids may be the most probable situation in the low dielectric 
environment of the inside of the membrane bilayer.  
Another observation from these studies modelling the interaction of CD16A 
with the CD247 dimer was that the dimer structure changes its organization and 
orientation, opening to accommodate the CD16A receptor. In this situation, CD247 
aspartic acids are now exposed and interact with receptor interface. This supports the 
idea that the presence of charged or polar residues in the transmembrane domain is 
unfavourable and these amino-acids have to be shielded either by dimerization or by 
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association with another molecule. Otherwise, exposed, unshielded charged residues 
mark unsuccessful or unassembled complexes to be recognized and shunted to 
degradation [258]. 
Furthermore, these observations also show that dimer structures are diverse 
and adaptable depending on the molecular context. Disulphide bonded molecules are 
not such restricted structures as previously reported [259] and allow at least some 
limited rotation and exposure of different residues to adjust to different scenarios. 
The data on how CD16A associates with the FcR1 and CD247 signaling 
adaptor molecules also show how there are different roles of charged residues within 
the lipid bilayer for each receptor. While it was widely accepted that charged residues 
were key for interactions, these data now show that the presence of charged residues 
in particular receptors is involved in quality control so that only fully assembled 
complexes exit ER/Golgi and reach the plasma membrane. Strikingly, NKp30 I/c and 
III/a were able to reach the plasma membrane in the absence of adaptor molecules, 
despite the presence of charged TM residues. The biochemical basis of this capacity is 
unclear, but the length and composition of the cytoplasmic tails of these receptors 
were important for this effect. It is interesting that even though NKp30 I/c and III/a 
could be expressed at the cell surface, receptor functionality still depended on being 
coupled to signaling modules (data not shown). 
The presence of a nonpolar, fluid hydrocarbon interior is one of the defining 
features of a lipid bilayer. However, many proteins possess charged or polar amino 
acid residues within their transmembrane domain. The incorporation of a charged 
amino acid side chain such as arginine from water to the interior of a membrane is 
expected to be unfavourable, primarily because of the high energetic cost of 
dehydrating the charge. Indeed, continuum electrostatics calculations that model the 
membrane as a slab of low dielectric material (e.g., oil) sandwiched by a high dielectric 
material (e.g., water) predict that the energetic penalty of moving a charge from water 
into a membrane is on the order of tens of kcal mol-1 [260]. 
To begin to understand how charged side chains can be accommodated in 
membranes, it is necessary to take a more detailed look at the membrane. The 
complete structure of a lipid bilayer, determined by joint refinement of X-ray and 
neutron scattering data, revealed that only roughly half of the bilayer, the innermost 3 
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nm or so, is occupied exclusively by hydrocarbon, while the remainder is a chemically 
heterogeneous mixture of lipid polar groups and water molecules [261]. Consequently, 
the bilayer–water interface is not an abrupt boundary between low and high dielectric 
media, but rather is a roughly 1.5nm region over which the polarity smoothly 
decreases from the high polarity of water to the low polarity of liquid hydrocarbon 
[261]. 
Thus, it is conceivable that the energetic cost of placing a charged side chain 
into a membrane could be greatly reduced if the side chain is located in a region of the 
membrane where it is solvated by water and lipid polar groups. In fact, the proximity 
of the charged residue to the outer leaflet of the plasma membrane seems also to be 
crucial. Interestingly, these effects of potentially charged residues appear to correlate 
with the high levels of free energy required to partition their potentially charged side 
chains from water into a lipid bilayer. Indeed, it has been previously confirmed that 
the placement of charged residues closer to the end or the upper part of the bilayer 
has a lesser effect on degradation and membrane targeting alterations than a more 
central location where a higher energy has to be overcome [258]. 
Regarding the observation that the CD16A receptor is shunted to degradation 
while a D205>A mutant accumulated in the ER and did not undergo degradation. It is 
known that charged residues in the TM of different proteins control their fate and 
degradation. Bonifacino and colleagues observed that incorporation of a charged 
residue, either R or D (in central positions, near the outer membrane leaflet it has little 
or no effect, which support that charged residues at TM has to be either shielded or 
this protein will be degraded), into a transmembrane protein renders it unable to 
reach cell surface and targets it for degradation.  
The analysis reported here demonstrates that placement of a single potentially 
charged residue within the transmembrane domain of a typical integral membrane 
protein can result in its retention and rapid degradation in the ER [258]. This is 
different to previous studies of the TCR subunits [39, 40], where these charged 
residues directly influence both protein-protein association and protein control. In the 
case of CD16A, the TM aspartic acid was controlling only turnover/ degradation/ ER 
exit, since no alteration in CD16A driven functions was noted in the CD16A D205>A 
mutant. 
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The precise position of charged residue in the lipid bilayer has not only 
implications for energetic cost, but also in determining the specific complex partner 
selected. For example, the FcεR1γ and DAP12 signaling modules are expressed by a 
variety of different cell types of hematopoietic origin and serve as signaling subunits 
for many different receptors. FcεR1γ and DAP12 exhibit a preference for particular 
basic side chain, FcεR1γ for arginine and DAP12 for lysine. However, the location of the 
ionizable TM residues also contributes to specificity of assembly, an aspect that is 
important because FcεR1γ and DAP12 are co-expressed by a number of different cell 
types. Genetic variation that allows binding to an incorrect signaling molecule could 
lead to novel responses with unpredictable consequences (Figure 6). 
One important question about this newly described mode of association is how 
different it is compared to the established widely known model for two component 
complexes one residue is involved per subunit and mutation of the interacting residues 
will totally abolish complex formation. For CD16A several TM residues are involved and 
the IVT and cellular experiments show that no single mutation abolishes receptor 
complex assembly totally, thus mutations or polymorphisms in single residues will 
have less effect so this novel model of 
receptor complex may then reflect a more 
evolutionarily robust interaction (Figure 
7A, B).  
However, it is also true that 
apparently minor amino acid changes, at 
positions that don’t participate directly in 
the interaction, can alter the proximity of 
the complex subunits and thus modulate 
complex formation. For example, close 
inspection of the interacting interfaces 
reveals a plausible explanation for how an 
apparently subtle difference between 
human and mouse CD247 TM sequences 
(a single isoleucine/leucine change) 
prevents the mouse version from 
Figure 6: Signaling adaptor molecule selectivity: 
CD16A receptor selectivity for adaptor molecules 
is not a random process. Precisely positioned 
charged residues within transmembrane domain 
restrict adaptor association to each receptor. 
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assembling with CD16A [218]. 
In the cell, receptors and signaling adaptor molecules are translated 
simultaneously. In the particular case of NK cells where there are many receptors that 
associate with either CD247 or FcεR1γ, these receptors may have to compete for 
adaptor molecules binding and the association mechanism may have an impact on 
association efficiency or speed. In this context, how single residue interactions 
compare to multiple residue interactions for the recruitment of adaptor molecules is 
not clear (Figure 7C). One way to test this hypothesis would be to use the IVT 
technique. In the proposed experiment, two mRNAs encoding different receptors (that 
bind a single adaptor molecule through the different interacting modes, e.g CD16A and 
IgA binding to FcR1) could be simultaneously expressed together with the adaptor 
molecule in a competition assay. If an excess of one receptor complex forms, 
compared to the other, this will reflect a stronger interaction. In cells, interpretation of 
such an experiment is more complex due to simultaneous occurring processes such as 
degradation, which will not be a problem in the IVT system. 
The role of TMD based signals in the quality control of misfolded membrane 
proteins in mammalian cells is also not fully understood. Novel approaches are being 
developed in order to characterize how membrane proteins are embedded into the 
plasma membranes and properly fold [262]. In these experiments, proteins are 
extracted from the bilayer using atomic force microscopy (AFM) based single-molecule 
force spectroscopy (SMFS) and its transfer into a new bilayer (which can already 
contain another, different protein) visualised. It would be also interesting to elucidate 
if the association between receptor complexes that involve multiple interactions 
follow an ordered sequence of events, or not, between the different residues 
involved in the association (Figure 7C). Perhaps the previously described experimental 
approach could be applied to fully characterize how multicomponent receptors are 
assembled in the ER/Golgi membrane. For example, CD16A receptors could be 
extracted from a bilayer and placed into a new one with a high density of the desired 
adaptor molecule to test if a controlled, orderly sequence of residue interactions 
exists.  
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Lastly, it is interesting to point out that generally receptors have positively 
charged residues and the adaptors negative ones. This might, in part, reflect that some 
of the signaling adaptor molecules are evolutionarily related, but it’s probably also 
relevant that the dielectric constant of the internal part of the membrane bilayer is 
such that arginine and lysine will likely be fully charged while aspartic and glutamic 
acids will often be protonated. Perhaps this explains why two acidic residues (from the 
adaptor dimer) are needed to offset a single basic amino-acid in the receptor.  
 
Figure 7: Receptor complexes association models: Schematic representation of different 
receptor based association models. Most immunoreceptors association rely on single residue 
interaction (A) meanwhile our novel model of receptor association for Fc receptors is based on 
multiple polar and aromatic interactions that extend the length of the transmembrane domain 
(B). Graphic representation of the possible ordered association for receptor complexes that 
interact by multiple interactions (C). Pink rectangle represents lipid bilayer in which receptor 
and signaling dimers are embedded. 
Over time, immune receptors have evolved differently so that some possess 
both recognition and intrinsic signaling modules, while others rely on a second 
element for signaling capacity. A fundamental issue is therefore to discuss what the 
possible reasons or advantages, if any, might justify the separation of ligand binding 
and signaling in two different elements. One possibility is that the separation of these 
functions adds a new point of control during receptor biogenesis, assembly and 
extracellular exposure. Only properly assembled complexes can reach the cell surface 
to signal. Another possibility is that for modular receptor complexes, changes in 
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extracellular sequence may modulate ligand recognition while maintaining signaling 
capacity, whereas alterations in the transmembrane domain can change the signaling 
molecule a receptor binds to and in consequence, link ligand recognition to a different 
cellular signaling network and so alter the functional consequences of receptor 
ligation. 
Generally, the novelty of these findings lies in the description of a completely 
new mode of assembly for immune receptors that can be applied more generally to 
other key receptors of the immune system. Only one of the four Fc receptors that 
require association with signaling adaptor proteins has the familiar basic TM residue 
that guides assembly of most modular activating immune receptors. These new data 
provide a plausible structural explanation for how the remaining three Fc receptors 
assemble with FcεRIγ and/or CD247 and show that at least two very distinct assembly 
mechanisms have arisen during evolution for the association of different receptors 
with the same set of signaling adaptors. Moreover, these data also provide a new view 
of the possible role of charged residues within a multicomponent modular receptor. 
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1. Cell surface expression of Natural Killer receptors CD16A and NKp30 is 
reduced in CD247 deficiency in a genotype-dependent manner, while NKp46 and 2B4 
expression remain normal. 
2. In the absence of the CD247 signaling molecule, the function of various NK 
cell receptors, including some that do and others that do not associate with CD247, is 
compromised, indicating that CD247 deficient patient NK cells are hyporesponsive. 
3. Patient T cell defects, together with the absence of CD247 protein correlate 
with impaired NK cell development and maturation, as shown by a dramatic decrease 
in KIR2D expression and elevated proportions of CD56bright and NKG2A/CD94+ cells. 
4. Detailed flow cytometric analysis of CD247 patient PBMCs revealed a 
minimal population of revertant T and NK cells with normal levels of TCR and CD247 
protein expression, respectively. 
5. Genetic analysis of patient cell cultures containing revertant cells showed 
extensive sequence variation in CD247 cDNAs and also identified genetic reversion due 
to a true back mutation and an upstream compensatory mutation, both compatible 
with CD247 expression allowing TCR reconstitution.  
6. Analysis of the patterns of sequence variability in control genes and PID 
genes where reversion events have or have not been described revealed that the 
propensity of genes to mutate influences the probability of spontaneous reversion of 
genetic defects in PID. 
7. The CD16A receptor interacts with CD247 and FcεR1γ signaling dimers via 
multiple aromatic and polar interactions between the transmembrane domains. This 
mode of transmembrane interaction is novel. Moreover, CD16A receptor showed no 
preference in signaling dimer recruitment, either CD247 or FcεR1γ. 
8. Analysis of CD16A membrane expression and function in different cell lines 
expressing wild-type receptor and mutants identified a dual function of the F202D205T206 
transmembrane element: while F202 and T206 residues support complex association, 
D205 controls receptor quality control. 
9. Modeling studies indicate that similar features underlie the association of 
CD64 and FcεR1α Fc receptors that also bind FcεR1γ and this was confirmed 
biochemically for the FcεR1α association with FcεR1γ. 
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1. En la deficiencia de CD247, la expresión en superficie de los receptores 
CD16A y NKp30 de las células NK disminuye en función del genotipo, mientras que la 
expresión de los receptores NKp46 y 2B4 es normal. 
2. En ausencia de la molécula de señalización CD247, la respuesta NK a través 
de distintos receptores está comprometida, formen o no complejo con CD247, lo que 
indica un defecto funcional de las células NK del paciente deficiente en CD247. 
3. Las células NK del paciente deficiente en CD247 muestran una gran 
disminución de la expresión de KIR2D, altos niveles de CD56bright y NKG2A/CD94+, lo 
que indica un desarrollo y maduración incorrectos de las NK. Este defecto se atribuye a 
la ausencia de células T funcionales junto a la carencia de proteína CD247 del paciente. 
4. El análisis detallado de los PBMCs del paciente deficiente en CD247 reveló la 
existencia de una pequeña población de células T y NK revertientes con niveles 
normales de TCR y CD247, respectivamente. 
5. El análisis genético de cultivos celulares del paciente, que contenían células 
revertientes, mostró una alta tasa de variación en el ADN codificante de CD247. Además, 
identificamos que dicha reversión tenía lugar por una retromutación y una mutación 
compensatoria, ambas compatibles con la expresión de CD247 y la reconstitución del TCR. 
6. Las diferencias entre los patrones de variabilidad de genes afectados en 
inmunodeficiencias primarias, con y sin eventos de reversión, respecto a genes 
control, indicaron que la propensión de un gen a mutar influye sobre la probabilidad 
de revertir de manera espontánea los defectos genéticos presentes en dicha patología. 
7. El receptor CD16A interacciona con los módulos de señalización CD247 y 
FcεR1γ a través de un nuevo modelo de asociación, basado en múltiples interacciones 
aromáticas y polares entre sus dominios transmembrana. Además, el receptor CD16A no 
muestra preferencia al reclutar y asociarse a uno de ambos módulos de señalización. 
8. El análisis en células NK de la expresión en superficie y la respuesta funcional de 
las diferentes construcciones de CD16A, permitió identificar una función dual del 
elemento transmembrana F202D205T206; mientras F202 y T206 median la formación del 
complejo, D205 regula el control de calidad del receptor. 
9. El modelo informático de los receptores de Fc, CD64 y FcεR1α, en asociación con 
FcεR1γ mostró que la formación de sus complejos se rige por características similares. Este 
hallazgo fue confirmado experimentalmente para la asociación de FcεR1α con FcεR1γ. 
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